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One-sentence summary: Ultra-low concentrations of ligand stimulate GPCR signaling that is distinct 
from that elicited by high concentrations of ligand. 
 
Editor's Summary: 
Ultra-sensitivity of GPCRs 
Most analyses of signaling through G protein–coupled receptors (GPCRs) are performed using 
nanomolar or micromolar concentrations of ligand. Civciristov et al. found that femtomolar 
concentrations of ligand activated signaling by the endogenous β2 adrenergic receptor (β2AR) and 
muscarinic acetylcholine receptor M3 (M3R) in several cell types. Such ultra-low concentrations of 
ligand stimulated signaling that was qualitatively distinct from that elicited by high concentrations and 
depended upon activation of pre-assembled GPCR complexes. In contrast, high concentrations of 
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ligand elicited signaling through GPCRs that were not part of complexes in addition to those in pre-
assembled complexes. These findings have important implications because drugs that target GPCRs are 
widely used therpeutically. 
 
 
Abstract 
G protein–coupled receptors (GPCRs) are the largest class of cell surface signaling proteins, participate 
in nearly all physiological processes, and are the targets of 30% of marketed drugs. Typically, 
nanomolar–micromolar concentrations of ligand are used to activate GPCRs in experimental systems. 
We detected GPCR responses to an extraordinarily wide range of ligand concentrations, from attomolar 
to millimolar, by measuring GPCR-stimulated production of cyclic adenosine monophosphate (cAMP) 
with high spatial and temporal resolution. Mathematical modeling showed that femtomolar 
concentrations of ligand can activate on average 40% of cells in the population provided that a cell can 
be activated by one to two binding events. In addition to cAMP, activation of the endogenous β2 
adrenergic receptor (β2AR) and muscarinic acetylcholine M3 receptor (M3R) by femtomolar 
concentrations of ligand in cell lines and human cardiac fibroblasts caused sustained increases in 
nuclear translocation of extracellular signal–regulated kinase (ERK) or cytosolic protein kinase C 
(PKC) activity, respectively. These responses were spatially and temporally distinct from those that 
occurred in response to higher concentrations of ligand and resulted in a unique cellular proteomic 
profile. This highly sensitive signaling depended on the GPCRs forming pre-assembled higher-order 
signaling complexes at the plasma membrane. Recognizing that GPCRs respond to ultra-low 
concentrations of neurotransmitters and hormones challenges established paradigms of drug action and 
provides a new dimension of GPCR activation that is quite distinct from that typically observed with 
higher ligand concentrations. 
 
Introduction 
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G protein–coupled receptors (GPCRs) are the largest class of signaling proteins at the cell surface. 
These receptors can sense a diverse range of stimuli – from photons and odors to hormones and large 
peptides – to induce intracellular signal transduction cascades that mediate specific cellular responses. 
GPCRs are ubiquitously distributed across all cell types, are involved in many diseases, and are the 
targets of 50% of marketed drugs (1). The intracellular domains of GPCRs interact with heterotrimeric 
G proteins, and agonist binding to GPCRs stabilizes an active receptor conformation that promotes the 
dissociation of the heterotrimeric G proteins into Gα and Gβγ subunits. The activated G proteins then 
interact with other intracellular effectors to induce downstream signaling. One of the downstream 
targets of activated Gα subunits is adenylyl cyclase (AC), which converts adenosine triphosphate (ATP) 
into cyclic adenosine monophosphate (cAMP).  However, it is increasingly clear that GPCRs do not 
exist in isolation. Instead, GPCR activity is closely coordinated by the assembly of receptors into 
higher-order protein complexes (e.g. (2-8)) that can restrict GPCR signaling to highly organized 
compartments within the cell, to activate receptor- and location-specific responses (2, 4, 9, 10). The 
spatial and temporal properties of these intracellular signals are very important for the control of 
distinct physiological outcomes (2, 4, 9-17). 
 
Although the assembly of GPCRs into protein complexes enables precise spatiotemporal control over 
signaling, the physical interactions between the receptor and other proteins in the complex are likely to 
alter the pharmacological properties of the GPCR itself. We previously reported that the relaxin 
receptor, RXFP1, pre-assembles into a large signaling complex that facilitates activation of the receptor 
by attomolar concentrations of relaxin (8). Whereas responses to such “ultra-low” concentrations of 
biologically active compounds are well-documented in cytokine signaling (18), such high ligand 
sensitivity for GPCRs is not widely reported. Typically, nanomolar–micromolar concentrations of 
ligand are used to activate GPCRs in experimental systems using global cellular measurements, such as 
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calcium mobilization or cAMP accumulation assays, as readouts for GPCR activity. Nevertheless, there 
are reports that some GPCRs, including the β2-adrenergic receptor (β2AR), opioid receptors, and 
angiotensin receptors, can respond to femtomolar (10-15M) concentrations of ligand in endogenous, 
physiological systems (19-26). Despite these observations, there is little mechanistic insight to explain 
these non-conventional responses, which are typically measured as changes in cell biology that occur 
far downstream of the receptor (such as cell adhesion or glucose uptake for the β2AR, analgesia or 
neuroprotection for opioid receptors, and blood vessel contraction for angiotensin receptors), because 
ultra-low ligand concentrations induce the same cellular responses or a subset of the responses as 
higher ligand concentrations. Without a detailed characterization of the putative extreme sensitivity of 
these important and ubiquitous receptors, it is unclear if this sensitivity is a widespread fundamental 
property of GPCRs and if ultra-low concentrations of ligands have a unique and physiologically 
relevant role in the cell. 
 
Here, by measuring endogenous GPCR activity with high spatial and temporal resolution, we detected 
responses from various GPCRs across an extraordinarily wide range of ligand concentrations from 
attomolar to millimolar. We found that two prototypical GPCRs, the β2AR and the muscarinic 
acetylcholine receptor M3 (M3R), were activated by femtomolar concentrations of ligand. Mathematical 
modeling predicted that femtomolar concentrations of ligand can feasibly activate on average 40% of 
cells in a population over a period of 5 min, as observed in our assays, provided that individual cells are 
capable of responding to 1–2 binding events. Signaling in response to femtomolar concentrations of 
ligand depended on the pre-assembly of a higher-order signaling complex at the plasma membrane. 
Compared to higher concentrations of ligand, receptor activation by femtomolar concentrations resulted 
in both a spatially and temporally distinct intracellular signal as well as a distinct response at the 
cellular level. The physical interaction between the GPCR and other proteins in the signaling complex 
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appeared to allosterically alter the pharmacological properties of the receptor to enhance the sensitivity 
to ligand. The ability of many prototypical GPCRs to respond to ultra-low concentrations of ligand 
suggests that a better understanding of this sensitivity is necessary for future research and drug 
discovery. 
 
Results 
Ultra-low concentrations of ligand activate endogenous GPCRs 
Typically, GPCR ligands within the nanomolar–micromolar concentration range are reported to 
activate receptors in experimental systems; however, there have been reports of GPCRs responding to 
femtomolar concentrations of ligand, which is well below conventionally defined pEC50 values, in 
endogenous physiological systems (e.g. (19-26)). We have previously shown that RXFP1 induces a 
biphasic increase in intracellular cAMP that is characterized by a remarkably wide range of pEC50 
values (10.9 aM vs. 0.3 nM) (8). This differs from typical biphasic response profiles, wherein each 
pEC50 value is closely clustered within the nanomolar–micromolar concentration range (27). To 
determine if this sensitivity to femtomolar (and lower) concentrations of ligand is a widespread 
property of GPCRs, we measured cAMP following activation of members of eight different GPCR 
families, six of which are present endogenously in HEK293 cells and, as negative controls, two for 
which we could not detect any mRNA (Fig. 1, A to C and fig. S1, A to H) (28, 29). HEK293 cells 
endogenously produce mRNA for the A2B adenosine receptor (activated by adenosine), the β1AR and 
β2AR (activated by isoproterenol, Iso) and α-adrenergic 2B and 2C sub-types, the EP1-4 prostanoid 
receptors (activated by prostaglandin E1, PGE1), the M3R (activated by carbachol, CCh), the delta 
opioid receptor (DOP, activated by SNC80) and the dopamine receptors, D2R and D4R (activated by 
dopamine). We found no transcripts encoding any of the receptors for relaxin (RXFP1-4) or the 
receptors for glucagon-like peptide 1 (GLP-1, GLP-2). The endogenous receptors canonically couple to 
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Gαs (adenosine A2B, β1AR, β2AR, the prostanoid, relaxin and glucagon-like peptide receptors) to 
stimulate AC activity, Gαi/o (α2B-AR, α2C-AR, DOP, D2R, and D4R) to inhibit AC activity, or Gαq/11 
(M3R) to stimulate Ca2+ mobilisation. Sub-nanomolar concentrations of adenosine, Iso, PGE1 (Fig. 
1A), CCh, SNC80, or dopamine (Fig. 1B) increased cAMP. As expected, there was no change in 
baseline cAMP in response to relaxin or glucagon-like peptide 1, both of which activate receptors that 
are not produced in HEK293 cells (Fig. 1C). For the endogenous receptors, we observed biphasic 
concentration-response curves ranging from attomolar to millimolar, in which the two response phases 
were separated by a very wide concentration range. All ligands caused an increase in cAMP at 
femtomolar concentrations (Table S1); when the ligand reached nanomolar concentrations, ligands that 
activated Gαs-coupled GPCRs caused a further increase in cAMP (Fig. 1A), whereas ligands that 
activated Gαi/o- or Gαq/11-coupled GPCRs decreased cAMP back to baseline (Fig. 1B). To determine if 
this characteristic biphasic response was cell type–specific, and as a further control, we repeated the 
same experiment in CHO-K1 cells. These cells do not endogenously produce adrenergic or muscarinic 
receptors (NCBI Gene Expression Omnibus accession GSE75521; (30)), and accordingly we observed 
no change in cAMP from baseline upon activation with Iso or CCh over a wide range of concentrations 
(fig. S2A). In contrast, we detected changes in cAMP following activation of members of four GPCR 
families that are produced endogenously (NCBI Gene Expression Omnibus accession GSE75521; (30)) 
in CHO-K1 cells (Fig. 1, D and E): the adenosine (A2A and A2B), prostanoid (EP1 and EP4), 5-
hydroxytryptamine (5-HT; 5-HT1B, 5-HT6, 5-HT7), and proteinase-activated (PAR1 and PAR2) 
receptors. Again, all ligands caused a biphasic change in cAMP from baseline: an initial increase in 
cAMP at femtomolar concentrations, followed by a further increase (adenosine, PGE1; Fig. 1D) or a 
decrease back to baseline (5-HT, thrombin; Fig. 1E) when the ligand reached nanomolar 
concentrations. These data suggest that sensitivity to ultra-low concentrations of ligand is a potentially 
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fundamental property of many endogenous GPCRs, irrespective of cell type and canonical G protein–
coupling profile. 
 
To further understand this highly sensitive signaling, we selected two prototypical GPCRs for detailed 
examination: the β2AR, a classical Gαs-coupled receptor that responds to Iso, and the M3R, a classical 
Gαq/11-coupled receptor that responds to CCh. To our knowledge, there are no reports of muscarinic 
receptors responding to femtomolar concentrations of ligand; however, there are previous reports that 
activation of the β2AR by picomolar concentrations of ligand (well below the EC50 values) leads to 
increased cell adhesion (19) and glucose uptake (20). Transcripts encoding both the β2AR and M3R are 
endogenously produced in HEK293 cells (fig. S1, C and E), and we confirmed localization of both 
proteins to the plasma membrane of HEK293 cells using fluorescent ligand binding (fig. S2, B and C). 
Sub-nanomolar concentrations of the endogenous β2AR or M3R ligands adrenaline or noradrenaline 
and acetylcholine, respectively, elicited similar increases in cAMP in HEK293 cells as did the synthetic 
ligands Iso and CCh (Fig. 1F). We observed the same biphasic response following addition of the 
β2AR-selective agonists salbutamol and formoterol (fig. S2D); no selective M3R agonists are available. 
Further, similar highly sensitive responses to Iso and CCh were observed in primary cultures of human 
cardiac fibroblasts that endogenously produce β2AR and M3R (Fig. 1G and fig. S2E). This highlights 
that activation of endogenous GPCRs by ultra-low concentrations of ligand is a general feature of at 
least some endogenous systems. To confirm that responses to ultra-low concentrations of ligand were 
receptor-dependent, we knocked down the endogenous β2AR or M3R in HEK293 cells; this abolished 
cAMP responses to sub-nanomolar concentrations of Iso or CCh, respectively (Fig. 1, H to K). 
Knockdown of β2AR had no effect on the cAMP response to CCh, and knockdown of M3R had no 
effect on the cAMP response to Iso (fig. S2, F and G). This confirms that receptor knockdown did not 
merely reduce baseline cAMP so that responses to sub-nanomolar Iso or CCh were undetectable, but 
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that cAMP responses to ultra-low concentrations of Iso or CCh required β2AR or M3R, respectively. 
Because responses to sub-nanomolar concentrations of ligand were undetectable by the cAMP assay 
following exogenous expression of the β2AR or M3R (Fig. 1L), we suggest that receptor 
overexpression may mask the responses to sub-nanomolar concentrations of ligand typically observed 
in endogenous systems. This could be because overexpressed receptors cause increased constitutive 
activity and therefore increase the baseline cAMP concentration within the cell (compare vehicle 
responses in Fig. 1, A and B to Fig. 1L). Alternatively, the overexpressed receptors may alter the 
composition of the signaling complexes that are required to respond to ultra-low concentrations of 
ligand (31), thus allowing the prototypical signaling response to dominate. 
 
We next wanted to determine whether ultra-low and high concentrations of ligand activated 
qualitatively different signaling pathways or only a quantitative difference in signaling. To address this 
we employed a sensitive plasma membrane–targeted cAMP Förster resonance energy transfer (FRET) 
biosensor (32) that allowed us to gain a higher resolution measure of cAMP produced at the plasma 
membrane in real time and in single live HEK293 cells. Activation of the endogenous β2AR by 1 fM 
Iso caused a relatively slow, gradual increase of cAMP at the plasma membrane (1.898 min-1) over 5 
min (Fig. 2, A and B). In contrast, a high concentration of Iso (100 nM) caused a more rapid increase in 
cAMP at the plasma membrane (0.666 min-1, 3-fold faster than responses to 1 fM Iso), which then 
declined (Fig. 2, A and B). Pre-incubation of the cells with 100 nM of ICI-118,551, an adrenergic 
receptor antagonist,  blocked the sustained plasma membrane cAMP response to 1 fM Iso (Fig. 2C and 
fig. S2H), further demonstrating the receptor-dependence of this signal. Whereas activation of the 
endogenous M3R by 1 fM CCh also caused a relatively slow, gradual increase in plasma membrane–
associated cAMP over 5 min, there was no response to a high concentration of CCh (1 µM; Fig. 2, D 
and E). The absence of a cAMP signal in response to a high concentration of CCh and the distinct 
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temporal profiles of cAMP generated by ultra-low vs high concentrations of Iso demonstrate that the 
signaling outcomes of high vs ultra-low concentrations are qualitatively different, and not merely due 
to changes in the amount of signaling (33). Pre-incubation of the cells with 10 nM N-methyl 
scopolamine (NMS, a muscarinic receptor antagonist) blocked the sustained plasma membrane cAMP 
response to 1 fM CCh (Fig. 2F and fig. S2H), confirming the receptor-dependence of this signal. 
Inhibiting Gαi/o proteins with NF023 had no effect on the cAMP response to Iso or CCh (fig. S2, I and 
J), suggesting that differences in signaling at high concentrations are not due to the activation of 
additional G proteins that inhibit cAMP production. Thus, endogenous β2AR and M3R induce sustained 
increases in cAMP at the plasma membrane in response to remarkably low concentrations of ligand. 
Critically, stimulating either the ultra-low or high concentration phases resulted in different temporal 
signaling profiles. 
 
Activation of GPCRs by femtomolar concentrations of ligand requires an intact orthosteric binding 
site 
In addition to the primary orthosteric binding site, many GPCRs have allosteric binding sites within the 
extracellular vestibule (a surface exposed area above the binding pocket), which can fine-tune receptor 
activity (34). All-atom molecular dynamic simulations have demonstrated that β2AR and M3R ligands 
make initial contact with this extracellular vestibule prior to achieving the final pose in the orthosteric 
binding pocket (35, 36). We therefore wondered whether this highly responsive state of the β2AR and 
M3R was due to ligand binding to an allosteric, high affinity binding site, or alternatively, to the 
canonical orthosteric site. 
 
In cAMP assays, the response to femtomolar concentrations of ligand was masked when the receptors 
were exogenously expressed (Fig. 1L). However, the plasma membrane–localized cAMP FRET 
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biosensor is more sensitive than the cAMP accumulation assay and has high spatial resolution, which 
allowed us to detect changes in cAMP abundance in single HEK293 cells in response to activation of 
exogenously expressed receptors by femtomolar concentrations of ligand (fig. S3, A to D). We used 
this approach to measure cAMP at the plasma membrane of single cells following transient expression 
of receptors bearing mutations in the orthosteric binding site. Mutation to alanine of a conserved 
orthosteric binding site residue within transmembrane domain three (D3.32A using Ballesteros-
Weinstein numbering (37), essential for ligand binding to aminergic receptors (38, 39)) of β2AR 
(D113A) and M3R (D148A) abolished plasma membrane cAMP in response to 1 fM or 1 pM ligand 
(Fig. 2, G and H and fig. S4, A to D). This mutation also inhibited canonical signaling in response to 
high concentrations of Iso and CCh (fig. S4, A and D). To confirm that the orthosteric site was 
necessary for responses to ultra-low ligand concentrations, we used a well-characterized mutant form 
of M3R called M3R-DREADD (M3R designer receptor exclusively activated by designer drugs), which 
is selectively activated by clozapine-N-oxide (CNO) but not other ligands (40, 41) (fig. S4E). 
Following expression of M3R-DREADD in cells, 1 fM CNO, but not CCh, increased plasma membrane 
cAMP (Fig. 2I and fig. S4E). Taken together, this confirms that activation of β2AR, M3R, and M3R-
DREADD by sub-nanomolar concentrations of ligand requires an intact orthosteric binding site. 
 
Mathematical modeling supports GPCR responses to femtomolar concentrations of ligand 
Cellular responses to such ultra-low concentrations of GPCR ligands are not commonly reported. 
However, we have clearly shown that these responses can occur in different cell lines, are observed 
using distinct cell assays, are receptor-dependent, and can be eliminated by mutation of the orthosteric 
binding pocket. To further explore the biophysics of receptor activation at such ultra-low ligand 
concentrations, we developed a mathematical model based on chemical kinetics and used it to 
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determine whether or not the observed cell activation by ultra-low concentrations of ligands can be 
explained by a simple ligand-receptor interaction. 
 
We considered a model wherein the activation of a cell is proportional to the number of occupied 
receptors. We also took into account the fraction of cells in the population that are competent to be 
activated by ligand (71.1%, determined from single cell FRET experiments using the high 
concentration of Iso; Fig. 2J). To simulate stochastic ligand-receptor binding kinetics in response to 1 
fM Iso we used Gillespie’s algorithm (42). We used a Markov chain Monte Carlo algorithm (MCMC) 
to sample potential parameter sets and used Bayesian statistics to estimate the probability distributions 
of the following parameters in our model: kr and kact (dissociation and activation rate constants, 
respectively), KD (equilibrium dissociation constant), and fc (fraction of cells competent for activation) 
(see Materials and Methods for model details; fig. S5, A to C). A detailed description of our procedure 
can be found in (43). MCMC sampling allowed us to calculate credible intervals for the time course of 
ligand binding in response to 1 fM Iso (Fig. 2K) and the number of binding events per cell (Fig. 2L). 
From this procedure, we determined the maximum a posteriori probability (MAP) parameter estimates 
(analogous to best-fit parameter estimates from non-linear regression). For the MAP parameter 
estimates, we found that over 70% of the cell population had less than two binding events, and less than 
10% had more than two binding events in the allotted time (Fig. 2L). The average number of binding 
events was slightly more than one per cell. Our model therefore suggests that it is feasible for cells to 
respond to femtomolar concentrations of ligand, but also predicts that the cells must be sufficiently 
sensitive (meaning that kact must be sufficiently large) to respond to just one or two binding events per 
cell. Such highly efficient and amplified signaling is commonly observed in response to cytokines (18). 
We then input the fastest published on-rate constant (1.2x1010 M-1min-1 for the µ-opioid receptor ligand 
carfentanil) and slowest published off-rate constant (4.8x10-4 min-1 for the M3R ligand tiotropium) for a 
GPCR ligand (44) to evaluate the capabilities of a “super ligand”. The model revealed that one binding 
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event per cell would occur in response to concentrations of the super ligand as low as 25 aM 
(attomolar, 10-18M). 
 
Responses to femtomolar concentrations of ligand depend on a pre-assembled signaling complex 
We hypothesized that the signal amplification required to cause cell activation in response to 1–2 
ligand binding events per cell may be achieved by the formation of highly specialized signaling 
complexes to allow rapid and more efficient coupling to intracellular pathways. We therefore sought to 
identify the signaling proteins involved in the cAMP response to femtomolar concentrations of Iso. The 
plasma membrane cAMP response was abolished following pharmacological inhibition of Gαs with 
NF449, of Gβγ with the peptide mSIRK, or of AC with 2’,5’-dideoxyadenosine (ddA), suggesting that 
femtomolar concentrations of Iso lead to activation of AC through Gαs and Gβγ to increase plasma 
membrane–associated cAMP (Fig. 3A and fig. S6, A and B). Consistent with our hypothesis, 
complexes formed by the β2AR and large scaffolding proteins such as A kinase anchoring protein 79 
(AKAP79), AKAP250, phosphodiesterases (PDEs), and β-arrestins are important for many responses 
to nanomolar concentrations of ligand (3, 5, 6). We found that the plasma membrane cAMP response to 
femtomolar concentrations of Iso depended on the scaffolding proteins AKAP250 and β-arrestins (Fig. 
3A and fig. S6, C to F).  
 
The plateau in the cAMP response to ultra-low ligand concentrations (Fig. 1, A, B and D to G) 
indicates that the balance between production and breakdown of the second messenger is tightly 
controlled. Whereas the proteins that are required for increased cAMP in response to activation of 
endogenous receptors are readily identified using inhibitors or genetic targeting, complications may 
arise when using the same approach to reveal proteins important for cAMP breakdown because any 
observed increase in basal cAMP activity could be due to the inhibitors affecting any of the multiple 
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endogenous receptor systems. However, by performing experiments in parallel in cells transiently 
expressing the β2AR, we can be more confident that any observed changes in baseline cAMP are due to 
a specific effect of the inhibitor on β2AR activity. The efficacy of this approach is illustrated by the 
identification of distinct proteins involved in the regulation of β2AR vs. M3R basal activity.  
 
Because the β2AR can also couple to inhibitory Gαi/o proteins, we first assessed the effect of the Gαi/o 
antagonist, NF023. Inhibition of Gαi/o increased vehicle-stimulated plasma membrane cAMP in native 
HEK293 cells (Fig. 3B and fig. S6G) and in HEK293 cells transiently expressing the β2AR (Fig. 3C 
and fig. S6H). The same effect was observed following ADP ribosylation of Gαi/o proteins by pertussis 
toxin (PTx; fig. S6, I and J). This suggests there is constitutive activity of the endogenous β2AR in 
these cells which is normally tonically opposed by the activity of Gαi/o. There was no additional 
increase in plasma membrane cAMP following stimulation with 1 fM Iso, suggesting that there is an 
upper limit for the induction of cAMP by the putative pre-assembled β2AR complex. Because cAMP 
can only be degraded by PDE activity, we next examined the effect of a PDE inhibitor, IBMX (3-
isobutyl-1-methylxanthine). In cells both endogenously (Fig. 3B and fig. S6K) and exogenously 
expressing the β2AR (Fig. 3C and fig. S6L), IBMX pre-treatment increased vehicle-stimulated plasma 
membrane cAMP, with no additional increase following stimulation with 1 fM Iso. We observed the 
same increase in constitutive plasma membrane cAMP activity following pharmacological inhibition of 
protein kinase A (PKA), which is activated by cAMP and often controls feedback inhibition pathways, 
with KT5720 (Fig. 3, B and C and fig. S6, K and L). PDE4D contributes a high proportion of PDE 
activity in HEK293 cells (45), and PKA activates the long isoforms PDE4D3 and PDE4D5 (46). Over-
expression of dominant negative (dn) forms of PDE4D3 (PDE4D3 dn) and PDE4D5 (PDE4D5 dn) 
caused an increase in vehicle-stimulated plasma membrane cAMP in native HEK293 cells (Fig. 3B and 
fig. S6, M and N). Whereas 1 fM Iso stimulated an additional increase in plasma membrane cAMP in 
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cells expressing PDE4D3 dn, there was no further increase compared to vehicle in cells expressing 
PDE4D5 dn. This suggested that although PDE4D5 may repress the constitutive activity of the putative 
pre-assembled β2AR complex, PDE4D3 merely decreases basal cAMP globally in the cell. Indeed, 
when we performed the same experiment in cells transiently expressing the β2AR, only co-expression 
of PDE4D5 dn, but not PDE4D3 dn, caused the same increase in vehicle-stimulated plasma membrane 
cAMP with no further increase in response to 1 fM Iso (Fig. 3C and fig. S6O). Because PKA is 
tethered in close proximity to the β2AR under resting conditions by the scaffolding protein AKAP79 
(3), we assessed the effect of AKAP79 knockdown on cAMP production. Knockdown of AKAP79 (fig. 
S6P) significantly increased vehicle-stimulated plasma membrane cAMP, and there was no further 
increase in plasma membrane cAMP following the addition of 1 fM Iso in native HEK293 cells (Fig. 
3B and fig. S6Q) and or in cells exogenously expressing the β2AR (Fig. 3C and fig. S6R). This 
suggests that AKAP79 plays an important role in repressing responses to 1 fM Iso. 
 
That the inhibition of proteins that repress cAMP production causes an increase in signaling under non-
stimulated conditions (Fig. 3, B and C) suggests both an inherent constitutive activity of the β2AR 
signaling complex, and that it may be pre-assembled under non-stimulated conditions. To confirm this, 
and to also identify the region of the receptor that interacts with other proteins in the complex, we 
performed glutathione S-transferase (GST) pulldowns using the intracellular regions of the β2AR (Fig. 
3D and fig. S7A). Under non-stimulated conditions, proteins required for activation (Gαs, AC2, β-
arrestin 1 and 2) and inhibition (Gαi, PKA, PDE4D5 and AKAP79) of the β2AR interacted with C-
terminal helix 8 (CT1, residues 330-357) (Fig. 3, E to G and fig. S7, A to D). Although we could not 
readily detect interactions with some proteins encoded by transcripts that occur at very low abundance 
in HEK293 cells (AC, AKAP79, and PDE4D; fig. S7E), exogenous expression of the protein of interest 
enabled detection of interactions with GST-CT1. This also revealed the involvement of AC2 in the 
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production of cAMP downstream of  β2AR: Gαs and Gβγ coincidently activate AC2, AC4, and AC7 
(47), and β2AR GST-CT1 pulled down exogenously expressed AC2-HA from cell lysates. Further, 
although we were unable to pull down Gαi from native HEK293 cell lysates, β2AR GST-CT1 pulled 
down endogenous Gαi from HEK293 cell lysates transiently expressing AC2-HA, PDE4D5 dn, or 
AKAP79-HA (Fig. 3, F and G and fig S7B). The propensity of AKAP250 to oligomerize (48) 
prevented pulldown of endogenous or exogenously expressed AKAP250, however, exogenously 
expressed HA-AKAP250 coimmunoprecipitated with the endogenous β2AR under non-stimulated 
conditions (Fig. 3H). To confirm that the β2AR signaling complex was pre-assembled at the plasma 
membrane in intact cells, we used acceptor photobleaching FRET to monitor interactions between cyan 
fluorescent protein (CFP)-tagged β2AR (β2AR-CFP) and some yellow fluorescent protein (YFP)-
tagged components of the complex (Gαs, AKAP79, β-arrestins 1 and 2, PKA) identified in signaling 
and GST pulldown experiments (Fig. 3I). We measured FRET within two regions of the plasma 
membrane for each cell analysed. Despite colocalization of proteins, FRET was not always detected in 
both regions of the plasma membrane (Table S2), suggesting the β2AR signaling complex is only 
formed in discrete membrane domains. Due to this non-uniform formation of the β2AR signaling 
complex, the data is not normally distributed. Analysis of the FRET efficiency revealed significant 
interactions at the plasma membrane under basal conditions between β2AR-CFP and Gαs-YFP and 
PKA-YFP, versus the negative control Gαq-YFP (Fig. 3J). Conversion of the data to binary values (0 = 
no FRET, 1 = FRET) revealed significant FRET between β2AR-CFP and all components tested: Gαs-
YFP, AKAP79-YFP, YFP-β-arrestin1, YFP-β-arrestin2, and PKA-YFP (Fig. 3J and fig. S7F). 
Therefore, a pre-assembled β2AR signaling complex responded to 1 fM Iso by stimulating Gαs-Gβγ 
activation of AC2 to increase cAMP in a manner that depended on AKAP250 and β-arrestins. This 
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cAMP production was tonically opposed by Gαi/o inhibition of AC2, and PKA stimulated PDE4D5 
activity in a manner that depended on AKAP79 (Fig. 3K). 
 
The cAMP produced in response to activation of the M3R by 1 fM CCh required a set of proteins 
distinct from those required for cAMP production downstream of the β2AR. There was no effect of Gαs 
inhibition on the plasma membrane cAMP response to 1 fM CCh (Fig. 4A and fig. S8A), suggesting 
that an alternate pathway can activate AC in this context. Activation of the M3R by micromolar 
concentrations of CCh induces a cAMP response that depends on a signaling complex comprising 
AKAP79, AC2, PKC, PKA, and Gαq/11 (7). Similarly, we found that the plasma membrane cAMP 
response to femtomolar concentrations of CCh was abolished following pharmacological inhibition of 
Gαq/11, Gβγ, PKC, and AC (Fig. 4A and fig. S8, A to C). Thus, for the M3R, ultra-low concentrations 
of ligand lead to Gαq/11-Gβγ activation of PKC, which stimulates AC to increase cAMP. In contrast to 
the β2AR complex, there was no effect of knockdown of AKAP250; however, knockdown of either β-
arrestin 1 or β-arrestin 2 abolished the plasma membrane cAMP response to 1 fM CCh (Fig. 4A and 
fig. S8, D to E). 
 
As observed for the β2AR (Fig. 3, B and C), inhibition of Gαi/o increased vehicle-stimulated plasma 
membrane cAMP in native HEK293 cells; however, 1 fM CCh stimulated a further increase in plasma 
membrane cAMP compared to the vehicle control (Fig. 4B and fig. S8F). This suggests that Gαi/o does 
not inhibit the pre-assembled M3R signaling complex. Indeed, in HEK293 cells transiently expressing 
the M3R there was no effect of the Gαi/o antagonist NF023 on the plasma membrane cAMP produced 
in response to vehicle or 1 fM CCh (Fig. 4C and fig. S8G). The same effect was observed following 
ADP ribosylation of Gαi/o proteins by PTx (fig. S8, H and I). In contrast, inhibition of PDEs or PKA 
increased vehicle-stimulated plasma membrane cAMP in both native HEK293 cells (Fig. 4B and fig. 
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S8J) and following transient expression of the M3R (Fig. 4C and fig. S8K), with no further increase in 
plasma membrane cAMP following stimulation with 1 fM CCh. This confirmed that the M3R also 
displays an inherent constitutive activity that is likely due to pre-assembly of a signaling complex, as 
identified for the β2AR. Expression of both PDE4D3 dn and PDE4D5 dn in native HEK293 cells 
caused a significant increase in vehicle-stimulated plasma membrane cAMP, with no further increase in 
plasma membrane cAMP in response to 1 fM CCh (Fig. 4B and fig. S8L). However, following co-
expression of the M3R, only PDE4D3 dn caused an increase in vehicle-treated plasma membrane 
cAMP with no further increase in response to 1 fM CCh (Fig. 4C and fig. S8M). Therefore, as for 
responses to high concentrations of CCh (7), PDE4D3 represses cAMP activity of the M3R. AKAP79 
was required for negative regulation of the β2AR complex. Although knockdown of AKAP79 increased 
vehicle-stimulated plasma membrane cAMP in native HEK293 cells (Fig. 4B and fig. S8N), it did not 
affect plasma membrane cAMP in response to vehicle treatment but did abolish the response to 1 fM 
CCh in cells transiently co-expressing the M3R (Fig. 4C and fig. S8O). Thus, as for cAMP responses to 
micromolar concentrations of CCh (7), an increase in cAMP in response to 1 fM CCh depended on 
AKAP79. 
 
To confirm that these proteins can pre-assemble with the M3R, we performed GST pulldowns from 
unstimulated HEK293 cell lysates and showed that proteins required for activation (Gαq/11, PKC, AC2, 
β-arrestins 1 and 2, AKAP79) and repression (PKA, PDE4D3) of ultra-sensitive M3R signaling 
required residues 305-457 of the third intracellular loop (ICL3) of M3R for assembly into a complex 
with the receptor (Fig. 4, D to G and fig. S9, A to D). As we observed with the β2AR, we could not 
detect endogenous interactions with some proteins encoded by transcripts that occurred at very low 
abundance in HEK293 cells (AC, AKAP79, and PDE4D; fig. S7E), but exogenous expression of the 
protein of interest enabled detection of interactions between these proteins and the GST-tagged regions 
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of M3R (Fig. 4, D to G and fig. S9, A to D). Again, as with β2AR ,this also revealed the involvement of 
AC2 in the stimulation of cAMP downstream of M3R. PKC and Gβγ can activate AC2 (47), and M3R 
GST-ICL3-2 pulled down exogenously expressed AC2-HA from cell lysates. We were unable to pull 
down PKC from native HEK293 cell lysates; however, endogenous PKC was pulled down by GST-
ICL3-2 from cell lysates transiently expressing AC2-HA, AKAP79-HA, or PDE4D3 dn (Fig. 4, D and 
G). As with the β2AR, to confirm pre-assembly of the M3R signaling complex at the plasma membrane 
of intact cells, we used acceptor photobleaching FRET between M3R-CFP and YFP-tagged 
components (Gαq, AKAP79, β-arrestins 1 and 2, PKA and PKC) of the signaling complex (Fig. 4H). 
Formation of the M3R complex did not always occur in regions of protein co-localization (Table S2), 
and the data was non-normally distributed, suggesting the M3R signaling complex forms in discrete 
regions of the plasma membrane. Analysis of the FRET efficiency revealed significant interactions 
between M3R-CFP and Gαq-YFP, YFP-β-arrestins 1 and 2, and YFP-PKC, versus the negative control 
Gαs-YFP (Fig. 4I). Following conversion of the data to binary values (0 = no FRET, 1 = FRET), we 
observed significant FRET between the M3R-CFP and all components tested: Gαq-YFP, AKAP79-
YFP, YFP-β-arrestin1, YFP-β-arrestin2, PKA-YFP, and YFP-PKC (fig. S9E). Therefore, a pre-
assembled M3R signaling complex responds to 1 fM CCh by stimulating Gαq/11-Gβγ-PKC–mediated 
activation of AC2 to increase cAMP in a manner that depends on AKAP79 and β-arrestins, and this 
cAMP is tonically opposed by PKA stimulated PDE4D3 (Fig. 4J). 
 
Together, these data reveal that although activation of the β2AR and M3R by femtomolar 
concentrations of ligand produces the same sustained increase in cAMP, the responses require pre-
assembly of signaling complexes comprising a distinct subset of proteins that associate with different 
regions of the receptors (Fig. 3K and 4J). 
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GPCRs activate sustained, compartmentalized signals in response to femtomolar concentrations of 
ligand 
Next we investigated if signaling in response to femtomolar concentrations of ligand extends to 
downstream pathways other than cAMP, if this signaling differs from that induced by high 
concentrations of ligand, and if this also occurs in human cardiac fibroblasts. We measured changes in 
ERK and PKC activity in different sub-cellular domains using FRET biosensors (that contain 
phosphorylation target sequences for ERK or PKC, respectively) targeted to different areas of the cell 
(49-51).  Activation of the endogenous β2AR in HEK293 cells and human cardiac fibroblasts did not 
affect the activity of cytosolic ERK, but increased nuclear ERK activity in individual cells (Fig. 5, A to 
D and fig. S10A). Mimicking the temporal dynamics of the cAMP response (Fig. 5, E and F), 1 fM Iso 
caused a sustained increase in nuclear ERK, whereas 100 nM Iso resulted in a transient increase (Fig. 5, 
A and D). There was no effect of 1 fM CCh on ERK activity in HEK293 cells (Fig. 5C) or in the 
cardiac fibroblasts (fig. S10B). In contrast, 1 fM CCh caused a sustained increase in cytosolic, but not 
plasma membrane-localized, PKC activity in both cell types (Fig. 5, G to J and fig. S10C); whereas a 
high concentration (1 µM) generated a transient increase in cytosolic PKC activity in both cell types 
and an increase in plasma membrane PKC activity in the cardiac fibroblasts (Fig. 5, G to J and fig. 
S10C). This again mimicked the temporal dynamics of the M3R cAMP response: 1 fM CCh caused a 
sustained increase in plasma membrane-localized cAMP, whereas 1 µM CCh induced a delayed and 
transient increase in plasma membrane cAMP that peaked at 15 min in HEK293 cells and at 5 min in 
the cardiac fibroblasts (Fig. 5, K and L). There was no effect of 1 fM Iso on PKC activity in the two 
cell types (Fig. 5I and fig. S10D). Therefore, activation of GPCRs by ultra-low concentrations of ligand 
also affects other intracellular signaling pathways in addition to cAMP production. In contrast to 
responses to high concentrations of ligand, this signaling is sustained and restricted to defined sub-
cellular compartments. This demonstrates that activation of GPCRs by ultra-low concentrations of 
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ligand induces signaling that is qualitatively different compared to the canonical responses activated by 
concentrations in the nanomolar to micromolar range. 
 
Activation of GPCRs by femtomolar concentrations of ligand causes a unique cellular response 
Both the location and duration of intracellular signals are extremely important for generating 
appropriate and distinct cellular responses (2, 4, 9). Because GPCR activation by femtomolar 
concentrations of ligand causes sustained signals in defined cellular compartments, this suggests that 
each femtomolar GPCR response may orchestrate a distinct cellular signal compared to both higher 
ligand concentrations and other ligands at femtomolar concentrations. Here we employed proteomic 
analysis by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) as a sensitive 
and global assessment of the consequences of activation of endogenous GPCRs by femtomolar 
concentrations of ligand in HEK293 cells. Activation of endogenous GPCRs induced a proteomic 
pattern that was unique to both the receptor that was stimulated and the ligand concentration (Fig. 6, A 
and B and Table S3). For the β2AR, the abundances of 56 proteins were uniquely affected by 1 fM Iso 
compared to vehicle or 100 nM Iso. From these, we identified proteins that were exclusively increased 
in response to 1 fM Iso, but not in response to 100 nM Iso or either concentration of CCh. These 
included five proteins that have roles in RNA processing and protein synthesis (Fig. 6C): SF3B5 
(splicing factor 3B subunit 5), a component of the spliceosome important for pre-mRNA splicing; 
TXNL4A (thioredoxin-like protein 4A), part of the machinery involved in spliceosome assembly; 
RPS21 (40S ribosomal protein 21), a component of the 40S ribosomal subunit; GUF1 (translation 
factor GUF1), promotes protein synthesis and acts as a fidelity factor during translation; and TXNDC9 
(thioredoxin domain-containing protein 9), which negatively impacts protein folding by inhibiting the 
ATPase activity of the chaperonin TCP1 complex. These results, in addition to the sustained increase in 
nuclear ERK activity (Fig. 5, A to C), suggested that ultra-low concentrations of Iso may affect gene 
expression. In agreement with the proteomic data, only 1 fM Iso, but not 100 nM Iso or CCh, increased 
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gene transcription over a period of 4 hours (Fig. 6, D and E) as assessed by a GFP reporter under the 
control of the constitutive EF1α promoter. We observed a similar increase in gene transcription in 
response to 1 fM Iso, but not 100 nM Iso or CCh, in human cardiac fibroblasts (Fig. 6, F and G). In 
HEK293 cells we observed no effect of inhibition of Gαi/o by NF023 on the lack of response to 100 nM 
Iso (fig. S10E). This shows that the absence of a signal in response to 100 nM Iso was not due to 
activation of inhibitory pathways and that therefore the responses to 1 fM and 100 nM Iso are 
qualitatively different. Together, these data demonstrate a unique role for increased gene transcription 
in cellular responses to the activation of the β2AR by femtomolar concentrations of ligand that is not 
triggered by higher concentrations of ligand. 
 
Similarly for the M3R, 1 fM CCh affected the abundances of 35 proteins in HEK293 cells compared to 
vehicle or 10 µM CCh. From these, we identified proteins that were exclusively increased in response 
to 1 fM CCh but unaffected by 10 µM CCh or either concentration of Iso. These included five proteins 
that affect trafficking, cytoskeletal networks and small G protein signaling (Fig. 6H): GGA1 (ADP-
ribosylation factor-binding protein), which plays a role in protein sorting and trafficking between the 
trans-Golgi network and endosomes; PDE6D (a cGMP PDE), which regulates the sub-cellular targeting 
of Ras small GTP-binding proteins; ILK (integrin-linked protein kinase), which is implicated in cell 
architecture, adhesion and anchorage-independent growth; VPS52 (vacuolar protein sorting-associated 
protein 52), which is a component of the retrograde transport and endocytic recycling machinery; and 
GPSM1 (G protein signaling modulator 1), a guanine nucleotide dissociation inhibitor which uncouples 
G protein signaling from GPCRs. These results suggested that ultra-low concentrations of CCh might 
be important for the regulation of cellular trafficking, cytoskeletal organization and signaling by small 
G proteins. To test this hypothesis we used Raichu-Cdc42, a FRET biosensor that reports on activation 
of the Rho GTPase Cdc42 (52); Rho GTPases are small G proteins that are important regulators of 
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trafficking and cytoskeletal organization (53). Indeed, in agreement with the proteomic data, over 4 
hours only 1 fM CCh caused an increase in Cdc42 activity, but 10 µM CCh, 1 fM Iso, and 100 nM Iso 
did not (Fig. 6, I and J). We observed the same increase in Cdc42 activity in response to 1 fM CCh, but 
not 10 µM CCh or Iso, in the human cardiac fibroblasts (Fig. 6, G and K). As seen for cAMP, 
inhibition of Gαi/o by NF023 did not alter the lack of response to 10 µM CCh (fig. S10F) in HEK293 
cells. This shows that 10 µM CCh did not increase Cdc42 activity and that the responses to 1 fM and 
10 µM CCh are qualitatively different. Therefore, activation of the M3R by femtomolar concentrations 
of CCh causes an increase in Cdc42 activity, which can impact many basic cellular processes including 
cell morphology, migration, endocytosis, and cell cycle progression (49). As seen for the β2AR, these 
data demonstrate that activation of the M3R by ultra-low ligand concentrations generates a unique 
cellular response compared to high ligand concentrations. 
 
 
Discussion 
The current findings uncover a previously unappreciated dimension of GPCR signaling, with several 
prototypical GPCRs initiating cellular responses to sub-nanomolar concentrations of ligand that are 
distinct from responses elicited by higher ligand concentrations. This extremely high sensitivity of 
GPCRs to ligand was observed in multiple cell types, was receptor-dependent, and required an intact 
orthosteric binding site in the receptor. Mathematical modeling suggested that these responses were 
triggered in an individual cell by one to two binding events, which would necessitate signal 
amplification. The pre-assembled signaling complexes we identified may play an important role in 
amplifying the response to individual receptor binding events by allowing highly efficient coupling to 
the signaling machinery. Activation of GPCRs by ultra-low concentrations of ligand caused sustained 
signals within defined subcellular compartments. In contrast, higher concentrations of ligand enabled 
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many more binding events to receptors both within and outside of complexes to generate qualitatively 
different responses at the whole-cell level (Fig. 7).  
 
Although a sensitivity to femtomolar concentrations of biological compounds is well below the 
accepted binding affinity of GPCRs, we were able to simulate stochastic ligand binding kinetics to 
reveal that the addition of femtomolar solutions of ligand under our assay conditions would result in, 
on average, roughly one binding event per cell over 5 min. This suggests firstly, that responses to ultra-
low concentrations of ligand are triggered by only a few GPCR molecules at the cell surface, and 
secondly, that activation of one–two receptors results in highly efficient signal amplification. Such 
signal amplification resulting from activation of only a few receptors at the cell surface is commonly 
observed for cytokine receptors (18). There are several ways in which such a high degree of signal 
amplification could occur. Our studies using inhibitors, GST pulldowns, and acceptor photobleaching 
FRET suggest that a pre-assembled, functional, higher-order signaling complex is essential for 
responses to ultra-low concentrations of ligand, and that the inherent activity of the GPCR is tightly 
controlled and limited. The close proximity of receptor, G proteins, and effectors to one another would 
allow a small number of activated receptors to cause a very rapid increase in signaling. Moreover, an 
assembled signaling complex may alter the local environment of a ligand near a receptor in such a way 
that the ligand spends more time in close proximity to the receptor, perhaps allowing a ligand to rebind 
to the receptor multiple times or to bind to the receptor for a longer time, thereby increasing the 
apparent sensitivity of the receptor to the ligand (54, 55). Indeed, the mere presence of β2AR at the 
plasma membrane of cells can more than double the local concentration of ligand (56). In addition, if 
these signaling complexes cluster due to oligomerization of AKAPs (48, 57), this would result in a high 
local concentration of receptors at the plasma membrane, with the clustered receptors effectively acting 
as a “ligand sink” to again increase the apparent receptor affinity. Finally, the protein-protein 
interactions within the complex may allosterically alter the properties of other associated proteins. This 
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could conceivably result in higher affinity binding by the receptor, by locking the transmembrane 
helices in an open conformation or reducing the dynamic fluctuations of the ligand binding site, to 
increase ligand accessibility to the binding pocket or to stabilize the ligand-receptor interaction to 
generate a signal robust enough to elicit a cellular response. In fact, binding of a positive allosteric 
nanobody to the intracellular regions of the β2AR can increase the affinity of β2AR for Iso by up to 
15,000-fold (58); this demonstrates that intracellular allosteric modulation of a subset of receptors 
could create two defined receptor populations with widely different ligand sensitivity. Allosteric 
interactions within the signaling complex may also lower the activation threshold of G proteins and 
other downstream effectors. Previous studies suggest that the association of PKC with AKAP79 locks 
the kinase into an active conformation, and PKC becomes insensitive to inhibitors that compete with 
ATP for binding to the kinase (59, 60). For the M3R, this heightened PKC activity could be very 
important for facilitating the efficient activation of AC2 by the kinase in response to ultra-low 
concentrations of CCh. 
 
The production, activity, and degradation of cAMP following stimulation of both the β2AR and M3R 
by femtomolar concentrations of ligand involves many proteins that are also required for responses to 
high concentrations of ligand (3, 5-7, 61). Although high-sensitivity responses are associated with 
many familiar components of GPCR signaling, the dynamics of the interacting proteins within the 
signaling complex must differ depending on the abundance of ligand to produce unique signaling 
outcomes. We found that the proteins of the pre-assembled β2AR complex interacted with the CT1 
region of the C-terminal tail of β2AR. This is consistent with previous reports of interactions between 
the C-terminal tail of the β2AR and proteins such as AKAP79, AKAP250, PKA, G protein receptor 
kinase 2 (GRK2), and Src (3, 61, 62). All proteins within the pre-assembled M3R complex interacted 
with the ICL3 domain of M3R. This is also consistent with previous reports of interactions between the 
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M3R ICL3 and proteins such as Gαq/11, Gβγ, phospholipase Cβ, GRKs, β-arrestins, and casein kinase 2 
(63-66). Moreover, conformational changes within this loop region are important for the formation of 
M3R dimers (67). For both the β2AR and M3R, a large number of proteins interact with the receptors 
through the same intracellular regions. However, crystal structures of the β2AR in complex with Gαs 
(68) and electron microscopy reconstruction of the β2AR in complex with β-arrestin (69) or a β2AR/V2 
vasopressin receptor chimera in complex with both Gαs and β-arrestin (70) suggest that there is little 
available space for any additional proteins to interact with a monomeric receptor. Nevertheless, these 
sorts of interactions may be feasible due to the highly flexible structure of AKAPs and the tendency for 
both AKAP250 and AKAP79 to form higher-order homo- and hetero-oligomeric structures (48, 57). 
AKAPs may therefore play an important role in supporting the efficient scaffolding of a large number 
of proteins. Consequently, we may envisage a higher-order assembly of a signaling complex that, by 
scaffolding a large number of effector proteins, generates a high amount of signal amplification in close 
proximity to the receptor. 
 
Responses to very subtle environmental cues have been described from bacteria to mammals. Some 
metalloregulatory proteins have femtomolar sensitivity to control zinc homeostasis in bacteria (71, 72), 
and it is proposed that Escherichia coli use sub-femtomolar zinc sensing to gain information about the 
host niche and form biofilms only in certain environments (73). Similarly, bacteria sense host iron as an 
environmental cue to express virulence factors (74); free iron is kept at ultra-low levels (10 yoctomolar; 
10-24M) in vertebrates (75), so bacterial siderophore proteins bind iron with extremely high affinity 
(enterobactin binds iron with a Kd of 10-35M) (76, 77). Here we show that mammalian cells can 
generate qualitatively unique responses to ultra-low concentrations of GPCR ligands. It is therefore 
tempting to speculate that the purpose of this high sensitivity is similar: to assess or sample the niche 
and tailor cellular phenotypes accordingly. Thus we could anticipate that cells exposed to ultra-low 
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concentrations of adrenaline may develop a phenotype distinct from cells that are exposed to ultra-low 
concentrations of acetylcholine. We suggest that this extremely large dynamic range of GPCR 
signaling is widespread throughout this receptor superfamily and that a low amount of continuous 
receptor activation may play a critical role in maintaining cell phenotypes in response to subtle 
environmental cues. The realization that many prototypical GPCRs respond to ultra-low concentrations 
of ligand has important implications for the current understanding of GPCR signaling and the drug 
design process. XX For example, current treatment regimens do not consider dosage to such low levels, 
or whether drugs can discriminate between isolated receptors or receptors assembled into protein 
complexes, as mechanisms for response specificity. This may go some way towards explaining the high 
attrition rates in GPCR drug development. Translation of these concepts could allow “repurposing” of 
existing drugs using tailored dosage or by targeting the drugs to specific protein complexes. 
 
Materials and Methods 
cDNAs 
AC2-HA (8) and AKAP79-HA (78) were described previously. The pEF1α-AcGFP-C1 vector was 
from Clontech, and human M3R and 3HA-M3R were from the Bloomsburg University cDNA Resource 
Centre (www.cdna.org). Human β2AR (79) was a gift from R Summers, and FLAG-β2AR (80) was a 
gift from R Lefkowitz. M3R-DREADD (Y149C, A239G) (40) was a gift from B Roth. Dominant 
negative PDE4D3 D484A (81) and PDE4D5 D556A (82) were gifts from M Houslay. HA-AKAP250 
(83) was a gift from C Malbon, and pSilencer and AKAP79 shRNA (59) were gifts from J Scott. 
 
pmEpac2 (32) was a gift from D Cooper. nucEKAR EGFP-mRFP (Addgene plasmid 18682) and 
cytoEKAR EGFP-mRFP (Addgene plasmid 18680) were gifts from K Svoboda (49). CytoCKAR 
(Addgene plasmid 14870) and pmCKAR (MyrPalm-CKAR, Addgene plasmid 14862) were gifts from 
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A Newton (50, 51). Raichu-Cdc42 (Raichu-Cdc42/Cdc42CT) was a gift from M Matsuda (52), and was 
contained within the pCAGGS vector (84), which was a gift from J Miyazaki. 
 
Gαs-YFP (Addgene plasmid 55781) and Gαq-YFP (Addgene plasmid 55782) were gifts from C Berlot 
(85). AKAP79-YFP (AKAP79 in a pEYFP-N1 vector) was a gift from M Dell’Acqua (86). YFP-β-
arrestin 1 and YFP-β-arrestin 2 were gifts from M Caron (87). PKA catalytic subunit-YFP (PKA-YFP) 
was a gift from M Zaccolo (88). YFP-PKC-βII-YFP (YFP-PKC; Addgene plasmid 14866) was a gift 
from A Newton (50). 
 
FLAG-β2AR D3.32A (D113A) and 3HA-M3R D3.32A (D148A) were generated using the Quikchange 
II kit (Agilent Technologies). The D3.32A annotation uses the Ballesteros-Weinstein numbering 
system (37). FLAG-β2AR-CFP and 3HA-M3R-CFP were generated by sub-cloning FLAG-β2AR and 
3HA-M3R into pECFP-N1. GST-tagged fragments of the β2AR and M3R intracellular regions were 
generated by amplifying the required region from the full-length cDNA using PCR, and cloning into 
pGEX-4T1. Shorter regions (β2AR-ICL1, β2AR-ICL2, M3R-ICL1 and M3R-CT1) were generated by 
annealing complementary primers, and cloning into pGEX-4T1. The following GST-tagged fragments 
of the β2AR were generated: ICL1 (residues 59-71), ICL2 (134-150), ICL3 (221-274), CT (330-413), 
CT1 (330-357), CT2 (358-386), and CT3 (387-413). The following GST-tagged fragments of the M3R 
were generated: ICL1 (91-104), ICL2 (165-185), ICL3 (256-489), ICL3-1 (256-304), ICL3-2 (305-
457), ICL3-3 (458-489), CT (546-590), CT1 (546-560), and CT2 (561-590). 
 
Drugs 
The vehicle for Iso, adrenaline, noradrenaline, dopamine and serotonin was 0.1% w/v ascorbic acid, 
present in experiments at a final concentration of 0.0001% w/v. The vehicle for CCh, adenosine, 
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salbutamol, acetylcholine and thrombin was ultra-pure (MilliQ) water and for CNO, PGE1, SNC80 and 
formoterol was DMSO, both present in experiments at a final concentration of 0.01% v/v. The vehicle 
for relaxin was 0.1% v/v trifluoroacetic acid, present in experiments at a final concentration of 
0.0001% v/v, and for glucagon-like peptide 1 was 0.025% v/v acetic acid, present in experiments at a 
final concentration of 0.000025% v/v. 
 
Cell culture 
HEK293 and CHO-K1 cells (ATCC; negative for mycoplasma contamination) were used as well-
characterized generic cell lines with endogenous expression of GPCRs. The cells were grown in 
DMEM supplemented with 5% v/v FBS. For HEK293 cells all assay dishes and plates were pre-coated 
with poly-D-lysine (5 µg/cm2). Primary cultures of human cardiac fibroblasts (ScienCell) were grown 
in poly-L-lysine coated culture flasks (2 µg/cm2) in DMEM supplemented with 5% v/v FBS, fibroblast 
growth supplement 2 (ScienCell), 100 U/mL penicillin and 100 µg/mL streptomycin. 
 
HEK293 cells were transfected using linear polyethyleneimine (PEI) (89). For experiments using single 
transfection of siRNA (AlphaScreen cAMP assay), cells were transfected with 25 nM scrambled, β2AR 
or M3R SMARTpool ON-TARGETplus siRNA (GE Dharmacon) using Lipofectamine 2000 
(Invitrogen). Human cardiac fibroblasts were transfected using X-tremeGENE 9 (Roche) at a 1:3 
DNA:transfection reagent ratio. 
 
RNA sequencing 
RNA was extracted from two passages of HEK293 cells (P0 and P37) using the RNeasy Mini Kit 
(Qiagen), and transcriptome sequencing was performed by the Beijing Genomics Institute. 
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cAMP quantification assay 
cAMP from cell populations was measured in duplicate using the AlphaScreen cAMP accumulation 
assay (PerkinElmer) as described previously (90) with the following modifications to ensure the 
maximum dynamic range and sensitivity. Cells were seeded into 96-well plates and grown to 
confluency. On the day of the experiment, cells were pre-incubated with stimulation buffer (HBSS with 
5 mM HEPES, 5.6 mM glucose, 1.3 mM CaCl2, 0.1% w/v BSA, pH 7.4) for 45 min at 37°C, prior to 
addition of ligands, vehicle or positive control (50 µM forskolin, 100 µM IBMX) diluted in stimulation 
buffer for 30 min at 37°C. For HEK293 cells and human cardiac fibroblasts, the experiment was 
performed in the absence of PDE inhibition; for CHO-K1 cells, the experiment was performed in the 
presence of 500 µM IBMX. To terminate the reaction, buffer was aspirated and 50 µL ice-cold ethanol 
was added per well. Following ethanol evaporation at 37°C, the cell precipitate was resuspended in 30 
µL detection buffer (5 mM HEPES, 0.3% Tween-20, 0.1% w/v BSA, pH 7.4; 130 µL for positive 
control samples), then 10 µL was transferred to a 384-well white OptiPlate (PerkinElmer) on ice. 
Following addition of anti-cAMP acceptor beads (in the presence of 500 µM IBMX) and donor beads 
with biotinylated cAMP for 1 h, the plate was read using an EnVision Multilabel Reader 
(PerkinElmer), and data analyzed against a standard curve using GraphPad Prism from n biological 
repeats as stated. 
 
qRT-PCR 
RNA was extracted from HEK293 cells and primary human cardiac fibroblasts using the RNeasy Mini 
Kit (Qiagen). qRT-PCR was performed in triplicate from 100 ng RNA using the iScript One-Step RT-
PCR Kit (Bio-Rad) and CFX96 Real Time System (Bio-Rad) according to manufacturer’s instructions. 
TaqMan probes (Applied Biosystems) used in this study were: ADRB2: Hs00240532_s1; CHRM3: 
Hs00265216_s1 and ACTB: Hs99999903_m1. The 2-ΔCT method (91) was used to analyze results and 
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data are expressed as 2-ΔCT (difference in Ct value of the gene of interest relative to the housekeeping 
gene, ACTB) from n biological repeats as stated. 
 
Fluorescent ligand binding 
HEK293 cells were seeded into black, optically clear 96-well plates and grown to 80% confluency. 
Cells were washed in PBS, then incubated with a nuclear stain (Hoescht 33342, Pierce) and a saturating 
concentration of antagonist (1 µM ICI-118,551 for β2AR binding or 100 µM N-methyl scopolamine for 
M3R binding) or vehicle control for 1 hour at RT. The fluorescent ligands (1 µM BODIPY-propranolol 
for β2AR binding or 100 nM BODIPY-pirenzipine for M3R binding, both from CellAura) were added 
for 10 min at RT. Buffer was removed from the cells and replaced with PBS prior to fluorescence 
imaging using a high-content PerkinElmer Operetta with an Olympus LUCPlanFLN 20x (NA 0.45) 
objective. Nuclei were visualized using the Hoescht 33342 filter set (excitation 360-400, emission 410-
480) and BODIPY fluorescence was visualized using the Cy5 filter set (excitation 620-640, emission 
640-680).  Four fields of view were captured per well and data were automatically analysed by 
determining the mean BODIPY fluorescence per well using Harmony High Content Imaging and 
Analysis software (v3.5.2). BODIPY fluorescence was expressed relative to the vehicle-treated control 
in triplicate from n biological repeats, as stated. 
 
High-content ratiometric FRET imaging 
Ratiometric FRET imaging was performed as described previously (9, 89, 92). We detected changes in 
cAMP levels using Epac2-camps (93) targeted to the plasma membrane (32) which undergoes a 
conformational change following cAMP binding to the cAMP-binding domain of Epac2. Changes in 
ERK or PKC activity were detected using EKAR or CKAR, respectively, which undergo 
conformational change following ERK or PKC phosphorylation of a target sequence. We used EKAR 
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targeted to the cytosol or nucleus (49), and CKAR targeted to the plasma membrane or cytosol (50, 51). 
Changes in Cdc42 activity were detected using Raichu-Cdc42 which undergoes a conformational 
change after GTP displaces GDP within residues 2-176 of Cdc42 (52). 
 
HEK293 cells were seeded in black, optically clear 96-well plates and grown to 70% confluency prior 
to transfection with PEI. Human cardiac fibroblasts were transfected using X-tremeGENE 9 in 
suspension and seeded in half area black, optically clear 96-well plates at 90% confluency. To measure 
activation of endogenously expressed receptors, HEK293 cells were transfected with 90 ng/well FRET 
biosensor and human cardiac fibroblasts were transfected with 100 ng/well FRET biosensor. For over-
expression of mutant receptors, HEK293 cells were co-transfected with 55 ng/well receptor and 40 
ng/well FRET biosensor. For experiments with siRNA, HEK293 cells were co-transfected with an 
additional 25 nM scrambled, β-arrestin 1, β-arrestin 2 or AKAP250 SMARTpool ON-TARGETplus 
siRNA (GE Dharmacon) for 72 hr. For experiments involving dominant negative constructs or shRNA, 
HEK293 cells were co-transfected with an additional 50 ng/well plasmid for 72 hr. Prior to the 
experiment, HEK293 cells were partially serum-restricted overnight in 0.5% FBS v/v DMEM. 
 
Cells were pre-treated with inhibitors for 30 min at 37°C in HBSS and inhibitors were used at the 
following concentrations: 100 µM ddA, 1 µM GF109203X, 100 µM IBMX, 1 µM KT5720, 5 µM 
mSIRK or mSIRK L9A, 10 µM NF023, 10 µM NF449, 100 nM UBO-QIC. Antagonists were pre-
incubated with the cells for 10 min, and were used at 100x the Ki (100 nM ICI-118,551 and 10 nM N-
methyl scopolamine). Cells were pre-treated with pertussis toxin (PTx; 100 ng/mL) at 37°C and 5% 
CO2 in 0.5% FBS v/v DMEM for 16 hr. 
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Fluorescence imaging was performed using a high-content GE Healthcare INCell 2000 Analyzer with a 
Nikon Plan Fluor ELWD 40x (NA 0.6) objective and FRET module as described (89). For CFP/YFP 
(pmEpac2, cytoCKAR, pmCKAR, Raichu-Cdc42) emission ratio analysis, cells were sequentially 
excited using a CFP filter (430/24) with emission measured using YFP (535/30) and CFP (470/24) 
filters, and a polychroic optimized for the CFP/YFP filter pair (Quad3). For GFP/RFP (cytoEKAR, 
nucEKAR) emission ratio analysis, cells were sequentially excited using a FITC filter (490/20) with 
emission measured using dsRed (605/52) and FITC (525/36) filters, and a polychroic optimized for the 
FITC/dsRed filter pair (Quad4). Cells were either imaged every 20 sec for 5 min (image capture of 5 
wells per 20 sec) or every 1 min for 20 min (image capture of 14 wells per min). At the end of each 
experiment, the same cells were stimulated with the following positive controls to maximally activate 
the biosensor: 10 µM forskolin, 100 µM IBMX with 100 nM PGE1 for Epac2, 200 nM phorbol 12,13-
dibutyrate (PDBu) for EKAR or 200 nM PDBu with phosphatase inhibitor cocktail (SigmaAldrich) for 
CKAR. Only HEK293 cells with >5% change in F/F0 (FRET ratio relative to baseline for each cell) 
after stimulation with positive controls were selected for analysis, and the data expressed relative to the 
positive control (F/FMax). For human cardiac fibroblasts, only cells with >3% change in F/F0 after 
stimulation with positive controls were selected for analysis, and data were expressed as the F/F0 due to 
the variation in responses to the positive controls. Data were analyzed using in-house scripts written for 
the FIJI distribution of ImageJ (94), as described (89). 
 
Ratiometric pseudocolor images were generated as previously described (95). A multiplication factor 
of 10 was applied using the Ratio Plus plugin, the Green Fire Blue LUT was applied, and the 
Brightness and Contrast range was set to the minimum and maximum FRET ratios within the image 
stack. The rate of cAMP increase over 5 min (Fig. 2A) was determined by fitting the plateau of the 
response using an exponential equation (plateau followed by one phase association) in GraphPad 
Prism. 
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ELISA 
HEK293 cells in 10 cm dishes were transfected with 3 µg pcDNA3.1, FLAG-β2AR, FLAG-β2AR 
D3.32A, 3HA-M3R or 3HA-M3R D3.32A, then seeded into 48-well plates 24 hours post-transfection. 
48 hours post-transfection, cells were washed with TBS (50 mM Tris pH 7.5, 150 mM NaCl), and fixed 
(4% paraformaldehyde in TBS, 30 min). Cells were washed in TBS, blocked (1% w/v skim milk, 0.1 M 
NaHCO3; 4 h, RT with shaking), then incubated with primary antibodies overnight at 4°C (mouse anti-
HA or anti-FLAG, both 1:2,000 in 0.1% w/v BSA in TBS). Cells were washed three times with TBS, 
then incubated with secondary goat anti-mouse-HRP antibody solution (1:2,000, 0.1% w/v BSA in 
TBS, 2 h, RT). SIGMAFASTTM OPD substrate solution (Sigma-Aldrich) was added and the reaction 
was terminated with 3M HCl. The samples were transferred to a 96-well plate and optical density at 
492 nm was measured using an EnVision Multilabel Reader (PerkinElmer). Data are expressed as the 
fold change in receptor expression compared to pcDNA3.1 transfected cells from n biological repeats 
as stated. 
 
Mathematical modeling 
Model definition 
The kinetics of ligand-receptor binding for a population of cells is defined by: 
      (1) 
where i is an index denoting a particular cell, L represents free ligand, R represents the unbound 
receptor, B represents the occupied receptor, and kf and kr are association and dissociation rate 
constants, respectively. Activation of a cell is taken to be proportional to the number of occupied 
receptors: 
      (2) 
L + R i
k f
kr
! ⇀!!↽ !! Bi
Bi +Ci kact⎯ →⎯ Bi +Ci*
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where kact is the activation rate constant, C represents an inactive cell and C* represents an active cell. 
Note that Ci has a value of 1 until activation and 0 thereafter. In addition to the kinetic parameters, we 
introduce fc, the fraction of cells competent to be activated by ligand. This parameter is introduced to 
account for any intracellular conditions (e.g. gene expression, cell cycle state etc.) that may prevent a 
cell from responding to ligand. 
 
Simulation 
For 1 fM Iso, we simulated the stochastic ligand-receptor binding kinetics using Gillespie’s algorithm 
(42). This approach is not computationally feasible when considering the high ligand concentration 
(100 nM), because the number of reaction events per unit time scales linearly with the number of 
molecules in the system (120,440/well for 1 fM vs. 1.2x1013/well for 100 nM). As we use molecule 
copy numbers in these simulations, the concentrations of biochemical species and the association rate 
constant, kf, must be converted to the appropriate units: 
       (3) 
        (4) 
where V is the extracellular volume (200 µL), M is a biochemical species and NA is the Avogadro 
constant. To estimate the concentration of occupied receptors ([B]) at high ligand concentration, we 
make a quasi steady-state approximation for the ligand-receptor interaction because the total ligand 
concentration, [LT], is much greater than the total receptor concentration, [RT]: 
      (5) 
 
We can also calculate the average concentration of occupied receptors per cell: 
#M = [M ]⋅NA ⋅V
k f ,# =
k f
NA ⋅V
[B]=[RT]⋅
k f [LT]
kr + k f [LT]
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        (6) 
 
The fraction of cells, FA, that are active after a time, t, is: 
        (7) 
with as the average rate of activation for each cell. For , all cells are 
activated in less than 1 min when [B]  [RT]. 
 
Parameter estimation 
We used a Bayesian approach to estimate the following parameters in our model: kr and kact, which are 
rate constants in the model defined above with units of s-1; KD, which is the equilibrium dissociation 
constant in molar units (M) for ligand-receptor binding and can be used to calculate kf, given kr; and fc, 
which is the fraction of cells competent for activation (dimension-less). 
 
Our procedure uses a Markov chain Monte Carlo (MCMC) algorithm to estimate the probability 
distribution of the parameters’ values similar to the procedure outlined in (43). In Bayesian statistics, 
this estimated distribution is called a parameter's posterior. For each parameter set sampled during the 
MCMC run, estimating the posterior requires calculating both the probability of observing the 
experimental data given a particular set of parameters (the likelihood) and the probability of the 
parameters given an assumed probability distribution (the parameter's prior distribution). 
 
Two parameters' means and standard deviations have already been characterized in the literature, log10 
KD (58) and kr (96). We assign log10 KD to have a normal distribution as its prior, with mean, µ, and 
standard deviation, σ: 
[Bi ] =
[B]
Ncells
FA = 1− e−λ⋅t
λ = kact ⋅ [Bi ] kact >10−4 s−1
⇡
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    (8) 
 
Assuming normality for kr results in significant probability density for values below zero. We therefore 
assign kr to have a gamma distribution as its prior, with the gamma distribution's parameters α and β 
calculated such that the distribution's mean, , and standard deviation, , correspond to the 
mean and standard deviation reported in the literature, 0.05 and 0.0255, respectively: 
       (9) 
      (10) 
     (11) 
 
The prior for the fraction of competent cells, fc, can be specified based on our data as follows. We 
assume that 100 nM Iso is a saturating dose that should activate all competent cells, and so we calculate 
the mean and standard deviation of the cells that are activated in response to 100 nM Iso (Fig. 2J) and 
assign fc to have the normal distribution: 
     (12) 
with µ and σ calculated from the data in Fig. 2J. The rate of receptor-dependent cell activation relies on 
incomplete knowledge of the relevant signaling pathways. However, we can still constrain this 
parameter with a uniformly distributed prior over a finite range. We assume that the activation rate 
must be sufficiently fast to activate cells given potential values of kr, and that excessively fast 
activation rates are not physically realizable. Thus, we set: 
      (13) 
 
P log10 KD( ) = Normal µ = −9.768,σ = 0.612( )
↵/ 
p
↵/ 2
α
β
= 0.05
α
β 2
= 0.02552
P kr( ) = Gamma α = 3.845,β = 76.894( )
P fc( ) = Normal µ = 0.711,σ = 0.092( )
P (log10 kact) = Uniform ( 4, 2)
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Other fixed parameters used in the model are volume of medium (200 µL/well), number of cells 
(30,000/well) and number of receptors (18,000/cell; (97, 98)). Our MCMC sampling was performed for 
1,000,000 iterations with a constant jump size of 0.2 (in log space), and we discarded the first 10,000 
points as the burn-in period. Parameter updates were accepted using the Metropolis-Hastings criterion, 
with approximately 37% of the attempted updates being rejected. The sampling trace for log10 KD 
appears to have reached stationarity (fig. S5A). From this, we can characterize the posterior distribution 
of each parameter; the posteriors for three of the four free parameters strongly reflect their priors (fig. 
S5B). The exception, kact, reveals a posterior that is shifted towards larger values, with near uniformity 
for parameters larger than 0.01. We can further characterize the correlations between the free 
parameters by looking at their pairwise scatter plots (fig. S5C). All pairwise relationships result in a 
Spearman's rank correlation coefficient, ρ, of less than 0.05, meaning that dependency between any 
pair of parameters is unlikely. 
 
Immunoblotting 
Proteins were resolved by SDS-PAGE using 10% Tris-glycine or pre-cast 4-15% Mini-PROTEAN 
TGX gels (for AKAP250 co-IP only; Bio-Rad) and transferred to 0.45 µm LF PVDF membranes (Bio-
Rad) using a Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad; 75 min, 10 V). Membranes were 
blocked for 1 hour at RT (5% w/v BSA for GST pulldowns or 5% w/v skim milk powder for 
confirmation of protein knockdown and overexpression or co-IP, in PBS with 0.1% v/v Tween-20, 
PBS-T), and incubated with primary antibody overnight at 4°C (diluted in 1% w/v BSA for GST 
pulldowns or 1% w/v skim milk powder for confirmation of protein knockdown and overexpression or 
co-IP, in PBS-T). Membranes were washed, incubated with secondary antibody (diluted in PBS-T for 
fluorescent secondary antibodies for GST pulldowns or 1% w/v skim milk powder in PBS-T for HRP-
conjugated secondary antibodies for confirmation of protein knockdown and overexpression or co-IP) 
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for 1 hour at RT, and washed. Immunoreactivity was detected by fluorescence for GST pulldowns 
(fluorescently-conjugated secondary antibodies) or ECL for confirmation of protein knockdown and 
overexpression or co-IP (Millipore, HRP-conjugated secondary antibodies). Fluorescence was detected 
using the Odyssey Classic Infrared Imager (LI-COR Biosciences), with resolution set at 169 µm and 
the intensity adjusted to be in the linear range for infrared fluorescence detection. ECL was detected 
using the ChemiDoc Touch Imaging System (Bio-Rad), with exposures adjusted to be in the linear 
range for chemiluminescence. 
 
Antibodies for immunoblotting 
Immunoblotting was performed using primary antibodies recognizing AKAP79 (Millipore ABS102; 
rabbit; 1:1,000), β-actin (Abcam ab36956; rabbit; 1:1,000), β-arrestin 1/2 (Cell Signaling 46745; 
rabbit; 1:1,000), β-arrestin 1 (Abcam ab31868; rabbit; 1:1,000), β-arrestin 2 (Millipore AB6022; rabbit; 
1:1,000), β-tubulin (Santa Cruz Biotechnology sc-9104; rabbit; 1:5,000), Gαi3 (Santa Cruz 
Biotechnology sc-262; rabbit; 1:1,000), Gαq/11 (Santa Cruz Biotechnology sc-392; rabbit; 1:1,000), Gαs 
(Millipore 06-237; rabbit; 1:1,000), gravin (AKAP250; Sigma-Aldrich G3795; mouse; 1:1,000), GST 
(Sigma-Aldrich G1660; mouse; 1:25,000), HA (Abcam ab9110; rabbit; 1:5,000), PDE4D (Abcam 
ab14613 for GST pulldowns or Santa Cruz Biotechnology sc-25814 for confirmation of protein 
overexpression; rabbit; 1:1,000), PKA (Santa Cruz Biotechnology sc-903; rabbit; 1:1,000), or PKC 
(Millipore 05-983; mouse; 1:1,000). Immunoblotting was detected using fluorescent or HRP-
conjugated secondary antibodies as follows: goat anti-mouse 680 (LI-COR 926-68070; 1:10,000), goat 
anti-mouse-HRP (Abcam ab97023; 1:2,000), goat anti-rabbit 800 (LI-COR 926-32211; 1:10,000), goat 
anti-rabbit-HRP (Cell Signaling 70745; 1:2,000 to detect β-arrestin 2, 1:5,000 to detect AKAP79, β-
arrestin 1/2 and PDE4D). 
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Confirmation of protein knockdown and dominant negative overexpression 
HEK293 cells were seeded into 6-well plates and grown to 70% confluency. Cells were transfected 
with 25 nM scrambled or targeted siRNA or 1.5 µg pcDNA/pSilencer, targeted shRNA or dominant 
negative cDNA for 72 hours using PEI. Following transfection, cells were lysed in 100 µL modified 
RIPA lysis buffer (50 mM Tris pH 7.4, 375 mM NaCl, 1 mM EDTA, 1% v/v Triton X-100, 0.5% w/v 
sodium deoxycholate, 0.1% w/v SDS) for 30 min on ice. Lysates were centrifuged (10,000g, 15 min, 
4°C), and protein concentration in the supernatant determined using the Bradford Ultra reagent 
(Expedeon). Laemmli sample buffer was added to the supernatants, and samples incubated at 37°C for 
30 min prior to immunoblotting. 
 
GST pulldowns 
GST-tagged fragments were expressed in BL21(DE3)pLys cells at 37°C following induction with 0.1 
mM IPTG. Cells were lysed by sonication (three pulses for 30 sec, 70% amplitude; Qsonica Q125) in 
lysis buffer (50 mM Tris pH 8, 300 mM NaCl, 10 mM MgCl2, 1 mM EDTA, 1 mM DTT, 0.25 mg/mL 
lysozyme, protease inhibitor cocktail, 100 U DNaseI). The homogenates were centrifuged (15,000g, 20 
min, 4°C) and the supernatants incubated with Glutathione Sepharose 4B resin (GE Healthcare; 1 h, 
4°C). The resin was washed (50 mM Tris pH 8, 150 mM NaCl, 1 mM EDTA, 1 mM DTT) until no 
protein remained in the eluate, then an equal volume of PBS (with protease inhibitors and 0.02% w/v 
NaN3) was added to the resin. 
 
HEK293 cells were seeded into 175 cm2 flasks and grown to confluency. For over-expression 
pulldowns, cells were transfected with 20 µg AKAP79-HA, PDE4D3 dn, PDE4D5 dn, AC2-HA or 
HA-AKAP250 using PEI. Cells were lysed in lysis buffer (50 mM Tris pH 7.4, 100 mM NaCl, 10% 
v/v glycerol, 0.3% v/v NP-40, 2 mM DTT, 1 mM PMSF, 1 mM benzamidine, 10 mM β-
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glycerophosphate, 2 mM Na3VO4, protease inhibitor cocktail, 100 U DNaseI) by rotating for 30 min at 
4°C, then passing 10 times through a 21-gauge needle. The cell homogenates were centrifuged (500g, 3 
min, 4°C), then incubated with the GST-β2AR or GST-M3R fragment resin for 4 hours at 4°C with 
rotation. The GST-β2AR or GST-M3R fragment resin was washed twice in lysis buffer (with 0.03% v/v 
NP-40), before the bound proteins were eluted in Laemmli buffer and incubated at 37°C for 30 min 
prior to immunoblotting. Immunoreactive bands were quantified by densitometry using Image Studio 
Lite 4.0 software (LI-COR Biosciences). Data for each fragment are normalized for equivalent amounts 
of GST, and expressed relative to GST alone control from n biological repeats as stated. 
 
Co-immunoprecipitation (co-IP) 
HEK293 cells in 175 cm2 flasks were transfected with 20 µg HA-AKAP250 using PEI. 48 hr post-
transfection, cells from eight flasks were lysed in modified lysis buffer (50 mM Tris pH 7.4, 100 mM 
NaCl, 10% v/v glycerol, 1% v/v Triton X-100, 0.5% v/v NP-40, 2 mM DTT, 1 mM PMSF, 1 mM 
benzamidine, 10 mM β-glycerophosphate, 2 mM Na3VO4, protease inhibitor cocktail, 100 U DNaseI) 
by rotating at 4°C for 20 min. The cell homogenates were centrifuged (16,000g, 10 min, 4°C), then 
halved and incubated with anti-HA affinity matrix (Roche Life Science) overnight at 4°C with rotation. 
The anti-HA affinity matrix was washed three times in lysis buffer, before the bound proteins were 
eluted in Laemmli buffer and incubated at 37°C for 30 min prior to immunobloting. 
 
Acceptor photobleaching FRET 
HEK293 cells were seeded in 6-well plates and grown to 70% confluency prior to co-transfection with 
0.6 µg/well FLAG-β2AR-CFP or 3HA-M3R-CFP and 0.6 µg/well of one of the following YFP-tagged 
proteins: Gαs-YFP, Gαq-YFP, AKAP79-YFP, YFP-β-arrestin 1, YFP-β-arrestin 2, YFP-PKC or PKA-
YFP. The FRET biosensor, pmEpac2, was used as a positive control. 4 hours post-transfection, cells 
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were re-seeded (40,000 cells/well) into a 8-well µ-slide (iBidi). 24 hours post-transfection, cells were 
rinsed in PBS, fixed (4% w/v paraformaldehyde, 30 min at RT), rinsed three times in PBS, then stored 
at 4°C. 
 
Acceptor photobleaching FRET was performed using a Leica SP8 confocal microscope with HCX PL 
APO 63x CS2 (NA 1.40) oil objective using the FRET Acceptor Photobleaching wizard in the LAS X 
software suite. A region of interest (ROI) was selected, and the acceptor channel bleached at 70% laser 
intensity (514 nm) until the YFP signal was reduced by at least 90%. CFP (UV 405 nm laser excitation, 
465-511 nm emission) and YFP (514 nm laser excitation, 532-603 nm emission) emission was then 
measured. For each biological replicate, three cells and two ROIs per cell were analysed (total 24 ROIs 
from four biological replicates). FRET efficiency was calculated by the LAS X software suite using the 
following equation: FRETeff = (Donorpost – Donorpre)/Donorpost. Gαq-YFP and Gαs-YFP were used as 
negative controls for FLAG-β2AR-CFP and 3HA-M3R-CFP FRET, respectively. Due to non-uniform 
distribution of protein complexes at the plasma membrane, and a large number of “0” FRET values, the 
data was not normally distributed and was therefore statistically analysed using a non-parametric 
Kruskal-Wallis test. For further analysis, data were converted to binary values (0 = no FRET, 1 = 
FRET) and analysed using a Chi-square test with two-sided P-values and 95% confidence interval. 
 
LC-MS/MS: FASP protein digestion and dimethyl labeling 
HEK293 cells were seeded in 6-well plates and grown to confluency. Cells were treated with vehicle or 
ligand for 4 h, then incubated in lysis buffer (100 mM Tris pH 7.6, 4% w/v SDS, 100 mM DTT) at 
95°C for 3 min, prior to sonication (30 sec, 30% amplitude, Qsonica Q125) and centrifugation 
(16,000g, 5 min, RT). 100 µg supernatant was digested using the FASP Protein Digestion Kit 
(Expedeon), with trypsin digestion overnight at 37°C. Digested peptides were labeled as previously 
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described (99) using 40 mM 12C3 light or 13C3 heavy formaldehyde with 20 mM NaCNBOH for 1 hour 
at 37°C, before the reaction was quenched with formic acid (to pH 2.5). The light- and heavy-labeled 
samples were mixed at a 1:1 ratio, and desalted using C-18 desalting columns and three washes with 
0.1% v/v formic acid. Samples were eluted in 70% v/v acetonitrile and 0.1% v/v formic acid, then dried 
by SpeedVac (LABCONCO). Peptides were fractionated following resuspension in Strong Anion 
Exchange (SAX) buffer (20 mM acetic acid, 20 mM phosphoric acid, 20 mM boric acid) pH 11 and 
loading onto stage tips containing five layers of anion exchange discs. The first fraction was collected 
following centrifugation (1,000g, 3 min, RT). A total of seven fractions were collected by sequentially 
eluting fractions from the stage tips in SAX buffer at pH 8, 6, 5, 4, 3 and SAX buffer 7 (10% v/v 
formic acid, pH 1). Fractions were dried, then resuspended in 2% v/v acetonitrile with 1% v/v formic 
acid by sonication at 37°C for 10 min prior to LC-MS/MS.  
 
Proteomic analysis by LC-MS/MS: Data collection and analysis 
Samples were analyzed by LC-MS/MS using a Q ExactiveTM or Q Exactive PlusTM Orbitrap mass 
spectrometer (Thermo Scientific) coupled online with an UltiMate 3000 RSLC nano-UHPLC (Thermo 
Scientific). Samples were injected onto an AcclaimTM PepMap100 RSLC C18 analytical column (100 
Å pore size, 75 µm i.d. x 50 cm reversed phase nanoViper column, Thermo Scientific) with 95% buffer 
A (0.1% v/v formic acid) at a flow rate of 250 or 300 nL/min. The peptides were eluted over 60 min 
using a gradient to 42.5% buffer B (80% v/v acetonitrile, 0.1% v/v formic acid). The eluate was 
nebulized and ionized using a Nano ElectroSpray Ion Source (Thermo Scientific) with coated 
borosilicate emitter and a capillary voltage of 1700 V. Peptides were selected for MS/MS analysis 
using XcaliburTM software (Thermo Scientific) in full MS/dd-MS2 (TopN) mode with the following 
parameter settings: MS AGC target 3E6, MS maximum injection time 120 ms, MS/MS TopN=10 or 
12, MS/MS AGC target 1e5, MS/MS maximum injection time 120 ms, normalized collision energy 27, 
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and isolation window of 2 or 1.8 m/z. Dynamic exclusion was set to 15 sec. Protein identification and 
quantification was performed using MaxQuant software (100) (version 1.5.3.17). Searches were 
performed against human sequences downloaded from UniProt (101) (August 2015 version) using the 
following parameters: specific digestion with trypsin with up to two missed cleavages, protein N-
terminal acetylation and methionine oxidation were set as variable modifications, and cysteine 
alkylation was set as a fixed modification. 
 
Data were analyzed using Perseus software (version 1.5.0.15). Common contaminants, reverse 
peptides, and proteins identified only by a modification site were removed. All data were expressed 
relative to vehicle-treated controls (heavy/light or transformed 1/[heavy/light], as appropriate), ratios 
were log2 normalized to allow quantitative analysis, and any non-valid values removed. Only proteins 
that differed significantly from vehicle controls (t-test with p<0.05) were retained and Z-scored to 
prepare the data for clustering. Hierarchical clustering was performed using default settings. Data for 
individual proteins are expressed as the log2 change relative to vehicle control from n biological repeats 
as stated. 
 
The proteins used for hierarchical clustering were further classified by their Biological Process 
GeneOntology (GO) term, using the Database for Annotation, Visualization and Integrated Discovery 
(DAVID, v6.7) (102, 103) to generate pie charts. Classifications with p-values <0.05 were used to 
group proteins according to biological function, synonymous classifications were removed, and the 
number of proteins classified within these groups were counted. Only classifications that were 
identified in at least two biological replicates were included within the final count. 
 
High-content EF1α-GFP imaging 
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HEK293 cells were seeded in black, optically clear 96-well plates and grown to 70% confluency prior 
to co-transfection with 50 ng/well pEF1α-AcGFP-C1 and 50 ng/well pDsRed-N1 (transfection 
efficiency control) using PEI. 24 hours post transfection, cells were washed with PBS and partially 
serum restricted in phenol red-free DMEM supplemented with 0.5% FBS v/v overnight. Human 
cardiac fibroblasts were transfected with 50 ng/well pEF1α-AcGFP-C1 and 50 ng/well pDsRed-N1 
(transfection efficiency control) using X-tremeGENE 9 in suspension, then seeded in black, optically 
clear 96-well plates at 90% confluency. Experiments in human cardiac fibroblasts used HBSS. 
 
Fluorescence imaging was performed using a high-content GE Healthcare INCell 2000 Analyzer with a 
Nikon Plan Fluor ELWD 40x (NA 0.6) objective. Sequential GFP/dsRed imaging used FITC 
(excitation 490/20, emission 525/36) and dsRed (excitation 555/25, emission 605/52) filters and the 
Quad4 polychroic. Baseline images were taken every 10 min for 40 min, cells were stimulated with 
ligand and images taken every 10 min for 4 hr. Data were analyzed by selecting 70 cells per well using 
FIJI, and the GFP fluorescence intensity was expressed relative to the average baseline GFP 
fluorescence intensity for each cell (F/F0). For human cardiac fibroblasts, all transfected cells were 
selected and data are expressed as relative fluorescence units (RFU) due to variation in transfection 
efficiency. 
 
Statistics 
All data points are the mean ± S.E.M. of at least three independent experiments unless otherwise stated. 
All data were analyzed using GraphPad Prism with statistically significant differences (p<0.05) 
determined using Kruskal-Wallis or Chi-square analysis (acceptor photobleaching FRET) or one- or 
two-way ANOVAs (all other experiments) with appropriate post-tests, as stated. 
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Figure S1. Endogenous expression of transcripts encoding GPCRs in HEK293 cells. 
Figure S2. Biphasic changes in cAMP are due to activation of endogenous β2AR and M3R.  
Figure S3. FRET biosensors can detect responses of endogenous or exogenous receptors to femtomolar 
concentrations of ligand.  
Figure S4. Plasma membrane localization and activity of mutant β2AR and M3R.  
Figure S5. Modeling responses to femtomolar concentrations of isopreterenol.  
Figure S6. Identification of proteins involved in mediating responses to 1 fM isopreterenol.  
Figure S7. The β2AR forms a pre-assembled signalling complex.  
Figure S8. Identification of proteins involved in mediating responses to 1 fM carbachol.  
Figure S9. The M3R forms a pre-assembled signalling complex.  
Figure S10. Femtomolar ligand concentrations activate compartmentalised signalling and unique cell 
responses.  
Table S1. Femtomolar concentrations of ligand increase cAMP.  
Table S2. The β2AR and M3R constitutively form complexes at the plasma membrane.  
Table S3. Proteins from hierarchical clustering analysis. 
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Figures 
 
Fig. 1. GPCRs respond to sub-nanomolar concentrations of ligand. (A–C) Quantification of cAMP 
in native HEK293 cells stimulated with increasing concentrations of adenosine, the βAR agonist 
isopreterenol (Iso), or prostaglandin E1 (PGE1) (A); the muscarinic acetylcholine receptor agonist 
carbachol (CCh), the delta opioid receptor agonist SNC80, or dopamine (B); and relaxin or glucagon-
like peptide 1 (C) in the absence of the PDE inhibitor IBMX. (n=6-9 independent experiments) (see 
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also Table S1). (D–E) Quantification of cAMP in native CHO-K1 cells stimulated with increasing 
concentrations of adenosine or PGE1 (D) and 5-hydroxytryptamine (5-HT) or thrombin (E) in the 
presence of IBMX. (n=6 independent experiments). (F) Quantification of cAMP in native HEK293 
cells stimulated with increasing concentrations of adrenaline, noradrenaline or acetylcholine in the 
absence of IBMX. (n=6-8 independent experiments) (see also Table S1). (G) Quantification of cAMP 
in primary human cardiac fibroblasts (CFs) stimulated with increasing concentrations of Iso or CCh in 
the absence of IBMX. (n=5-6 independent experiments). (H) Quantification of cAMP in native 
HEK293 cells or HEK293 cells transiently expressing scrambled or β2AR siRNA, stimulated with 
increasing concentrations of Iso in the absence of IBMX. (n=6 independent experiments). (I) 
Expression of β2AR mRNA in native HEK293 cells or HEK293 cells transiently expressing scrambled 
(scram.) or β2AR siRNA as determined by qRT-PCR. (n=3 independent experiments). (J) 
Quantification of cAMP in native HEK293 cells or HEK293 cells transiently expressing scrambled or 
M3R siRNA, stimulated with increasing concentrations of CCh in the absence of IBMX. (n=6 
independent experiments). (K) Expression of M3R mRNA in native HEK293 cells or HEK293 cells 
transiently expressing scrambled (scram.) or M3R siRNA as determined by qRT-PCR. (n=3 
independent experiments). (L) Quantification of cAMP in HEK293 cells transiently expressing the 
β2AR or M3R and stimulated with increasing concentrations of Iso or CCh, respectively, in the absence 
of IBMX (n=3-4 independent experiments). All data are expressed as the mean ± S.E.M. of n 
independent experiments. * p<0.05 and ** p<0.01 versus HEK293 controls, one-way ANOVA with 
Tukey’s multiple comparison test.  
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Fig. 2. Femtomolar concentrations of ligand cause sustained increases in plasma membrane-
localized cAMP and require an intact orthosteric binding site and only one binding event per cell. 
(A) Measurement of cAMP at the plasma membrane in single native HEK293 cells using the FRET 
biosensor, pmEpac2, which reversibly binds cAMP. Cells were stimulated with vehicle, 1 fM Iso, or 
100 nM Iso. (n=47-79 cells). (B) Representative ratiometric pseudocolor images of cells from (A) at 
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the indicated time points following stimulation. Scale bar, 10 µm.  (C) Measurement of cAMP at the 
plasma membrane in single native HEK293 cells pre-incubated with the β2AR antagonist ICI-118,551 
before stimulation with vehicle or 1 fM Iso. (n=51-97 cells). (D) Measurement of cAMP at the plasma 
membrane in single native HEK293 cells stimulated with vehicle, 1 fM CCh, or 1 µM CCh. n=29-53 
cells. (E) Representative ratiometric pseudocolor images of cells from (D) at the indicated time points 
following stimulation. Scale bar, 10 µm (F) Measurement of cAMP at the plasma membrane in single 
native HEK293 cells pre-incubated with the M3R antagonist N-methyl scopolamine (NMS) before 
stimulation with vehicle or 1 fM CCh.  (n=56-95 cells). (G) Measurement of cAMP at the plasma 
membrane in single HEK293 cells transiently expressing wild-type (WT) FLAG-β2AR  or the 
orthosteric binding site D3.32A mutant FLAG-β2AR and stimulated with vehicle, 1 fM Iso, or 1 pM 
Iso. (n=43-151 cells). (H) Measurement of cAMP at the plasma membrane in single HEK293 cells 
transiently expressing WT or D3.32A mutant 3HA-M3R and stimulated with vehicle, 1 fM CCh, or 1 
pM CCh. (n=119-186 cells).  (I) Measurement of cAMP at the plasma membrane in single HEK293 
cells transiently expressing M3R-DREADD and stimulated with vehicle, 1 fM CCh, or 1 fM CNO. 
(n=57-89 cells). All cells were stimulated at 0 min, and a maximal cAMP response (Max.) was induced 
after 5 min by stimulating the cells with forskolin, IBMX, and PGE1. Individual cells were analyzed 
from experiments performed on three independent occasions. Data are expressed as the mean ± S.E.M. 
of n cells, normalized to the maximal cAMP response induced after 5 min (F/FMax). (J) Fraction of 
HEK293 cells within the field of view that increased cAMP at the plasma membrane following a 5 min 
exposure to 1 fM or 100 nM Iso. Data were analyzed from experiments in Fig. 3, A and B, with an area 
under the curve (AUC) of greater than 0.697 considered significantly increased compared to vehicle 
control. Data are expressed as the mean ± S.E.M. of 6 independent experiments. (K) The 95% credible 
interval for responses to 1 fM Iso over 5 min, using 1,000 randomly subsampled parameter sets from 
the MCMC sampling procedure. The red line shows the time course with parameters consistent with 
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the maximum a posteriori probability (MAP) estimate. The solid grey line shows the median, and the 
dashed grey lines show the 95% credible interval for the sub-sampled parameter sets. The 1 fM Iso data 
from (J) is shown as crosses; for two of these only a small region (~2%) of sampled parameter space 
allows the model to reach these points. (L) Normalized frequency of binding for 1 fM Iso from 100 
independent model simulations with the MAP estimate parameter set. The average number of binding 
events is 1.13 per cell.  
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Fig. 3. A pre-assembled β2AR signaling complex controls the response to femtomolar 
concentrations of ligand. (A) Measurement of cAMP at the plasma membrane in response to 5 min of 
 62 
stimulation with vehicle or 1 fM Iso in single native HEK293 cells that were pre-treated with the Gαs 
antagonist NF449, the Gβγ inhibitor mSIRK, the negative control peptide mSIRK L9A, or the AC 
inhibitor 2’,5’-dideoxyadenosine (ddA) or transient expression of scrambled (scram.), AKAP250, β-
arrestin 1, or β-arrestin 2 siRNA. (n=36-254 cells). (B) Measurement of cAMP at the plasma 
membrane in response to 5 min of stimulation with vehicle or 1 fM Iso in single native HEK293 cells 
were pre-treated with the Gαi/o antagonist NF023, the PDE inhibitor IBMX, or the PKA inhibitor 
KT5720 or transient expression of PDE4D3 dominant negative (dn), PDE4D5 dn, pSilencer control, or 
AKAP79 shRNA. (n=22-254 cells). (C) Measurement of cAMP at the plasma membrane following 5 
min of stimulation with vehicle or 1 fM Iso in HEK293 cells transiently expressing the β2AR. Cells 
were pre-treated with the Gαi/o antagonist NF023, the PDE inhibitor IBMX, or the PKA inhibitor 
KT5720 or transient coexpression of PDE4D3 dn, PDE4D5 dn, pSilencer control, or AKAP79 shRNA. 
(n=22-153 cells). All cells (A–C) were stimulated at 0 min, and a maximal cAMP response (Max.) was 
induced after 5 min by the addition of forskolin, IBMX, and PGE1. Individual cells were analyzed from 
experiments performed on three independent occasions.  Data are expressed as the mean ± S.E.M. of n 
cells and represented as the 5 min area under the curve (AUC). *** p<0.001 versus vehicle control, 
two-way ANOVA with Sidak’s multiple comparison test; ^^ p<0.01 and ^^^ p<0.001 versus untreated 
control, two-way ANOVA with Dunnett’s multiple comparison test. (D) Cartoon showing the regions 
of the β2AR C-terminal tail (CT) that were tagged with GST. (E) Quantification of proteins identified 
as required for activation of cAMP in response to 1 fM Iso in GST pulldowns from lysates of 
unstimulated native HEK293 cells using the indicated CT-GST fusions. GST pulldowns were assayed 
for endogenous Gαs (short and long forms), transgenically expressed HA-AC2, endogenous β-arrestin 
1, and endogenous β-arrestin 2. (n=5-6). (F) Quantification of proteins identified as required for 
regulation of constitutive activity of the pre-assembled β2AR complex in GST pulldowns from lysates 
of unstimulated native HEK293 cells using the indicated CT-GST fusions. GST pulldowns were 
 63 
assayed for endogenous Gαi (in cells transgenically expressing AKAP79-HA), endogenous PKA, 
transgenically expressed PDE4D5 dn, and transgenically expressed AKAP79-HA. (n=3-4). For GST 
pulldown assays (E–F), band densities were normalized for equivalent amounts of GST and expressed 
relative to GST alone. Data are mean ± S.E.M. of n independent experiments. * p<0.05 and *** 
p<0.001 versus GST alone, two-way ANOVA with Dunnett’s multiple comparison test. (G) 
Representative immunoblots (IB) showing Gαs, β-arrestin 1, β-arrestin 2, PKA, PDE4D, HA and Gαi 
in GST pulldown assays of lysates from cells using GST alone or the indicated CT-GST fusions. (H) 
Representative immunoblots showing β2AR and HA following HA immunoprecipitation (IP) of lysates 
from HEK293 cells transiently expressing HA-AKAP250. (I) Representative images of cells co-
expressing β2AR-CFP and a YFP-tagged component of the β2AR–associated complex or the positive 
control pmEpac2, following acceptor photobleaching of a region of the plasma membrane (dotted box). 
Grey solid boxes indicate areas of the plasma membrane that were photobleached previously. Scale bar, 
10 µm. (J) FRET efficiency at the plasma membrane between β2AR-CFP and YFP-tagged components 
of the protein complex, calculated from acceptor photobleaching FRET experiments from two regions 
of interest (ROI) per cell with four cells analyzed per biological replicate. (n=24 ROIs). Data are 
expressed as the mean ± S.E.M. of n ROIs. * p<0.05 and *** p<0.001 versus β2AR-CFP/Gαq-YFP 
FRET efficiency, Kruskal-Wallis with Dunn’s multiple comparison test; ^^ p<0.01 and ^^^ p<0.001 
versus β2AR-CFP/Gαq-YFP FRET following conversion to binary values (1 = FRET, 0 = no FRET) 
then Chi-square test. (K) Cartoon of the pre-assembled β2AR signaling complex required for responses 
to femtomolar concentrations of Iso. Stimulation of cells with 1 fM Iso activates a Gαs and Gβγ–
mediated stimulation of AC2 that depends on AKAP250 and β-arrestins 1 and 2. This increase in 
cAMP causes the sequential activation of PKA and PDE4D5, which cooperates with Gαi/o to oppose 
the increase in cAMP. This tonic opposition depends on AKAP79. Hierarchy of proteins within the 
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cartoon is based on whether proteins mediate activation or inhibition and reported protein-protein 
interactions (3, 5, 53, 59, 104, 105).  
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Fig. 4. A pre-assembled M3R signaling complex controls the response to femtomolar 
concentrations of ligand. (A) Measurement of cAMP at the plasma membrane in response to 5 min of 
stimulation with vehicle or 1 fM CCh in single native HEK293 cells that were pre-treated with the Gαs 
antagonist NF449, the Gαq/11 inhibitor UBO-QIC, the Gβγ inhibitor mSIRK, the negative control 
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peptide mSIRK L9A, the PKC inhibitor GF109203X, or the AC inhibitor 2’,5’-dideoxyadenosine 
(ddA) or transiently transfected with scrambled (scram.), AKAP250, β-arrestin 1 or β-arrestin 2 
siRNA. (n=39-316 cells). (B) Measurement of cAMP at the plasma membrane in response to 5 min of 
stimulation with vehicle or 1 fM CCh in single native HEK293 cells that were pre-treated with the 
Gαi/o antagonist NF023, the PDE inhibitor IBMX, or the PKA inhibitor KT5720 or transiently 
transfected with PDE4D3 dn, PDE4D5 dn, pSilencer control, or AKAP79 shRNA. (n=31-316 cells). 
(C) Measurement of cAMP at the plasma membrane following 5 min of stimulation with vehicle or 1 
fM CCh in HEK293 cells transiently expressing the M3R. Cells were pre-treated with the Gαi/o 
antagonist NF023, the PDE inhibitor IBMX, or the PKA inhibitor KT5720 or transiently co-transfected 
with PDE4D3 dn, PDE4D5 dn, pSilencer control, or AKAP79 shRNA. (n=65-193 cells). All cells (A–
C) were stimulated at 0 min, and a maximal cAMP response (Max.) was induced after 5 min with 
forskolin, IBMX, and PGE1. Individual cells were analyzed from experiments performed on three 
independent occasions. Data are expressed as the mean ± S.E.M. of n cells, and represented as the 5 
min area under the curve (AUC). ** p<0.01 and *** p<0.001 versus vehicle control, two-way ANOVA 
with Sidak’s multiple comparison test; ^^ p<0.01 and ^^^ p<0.001 versus untreated control, two-way 
ANOVA with Dunnett’s multiple comparison test. (D) Cartoon showing the regions of the M3R third 
intracellular loop (ICL3) that were tagged with GST.  (E) Quantification of proteins required for 
activation of cAMP in response to 1 fM CCh in GST pulldowns from unstimulated native HEK293 
cells using the indicated ICL3-GFP fusions. GST pulldowns were assayed for endogenous Gαq/11, 
endogenous PKC (from cells transgenically expressing with AKAP79-HA), transgenically expressed 
HA-AC2, endogenous β-arrestin 1, endogenous β-arrestin 2 and transgenically expressed AKAP79-HA 
(n=3-4). (F) Quantification of GST pulldowns from unstimulated native HEK293 cell lysates of 
proteins required for regulation of constitutive activity of the pre-assembled M3R complex: endogenous 
PKA and transgenically expressed PDE4D3 dn (n=3-4). For GST pulldown assays, band densities were 
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normalized for equivalent amounts of GST, and expressed relative to GST alone. Data are mean 
± S.E.M. of n independent experiments. * p<0.05, ** p<0.01 and *** p<0.001 versus GST alone, two-
way ANOVA with Dunnett’s multiple comparison test. (G) Representative immunoblots (IB) showing 
Gαq/11, PKC, HA, β-arrestin 1, β-arrestin 2, PKA, and PDE4D in GST pulldown assays of lysates using 
GST alone or the indicated ICL3-GST fusions . (H) Representative images of cells co-expressing M3R-
CFP and a YFP-tagged component of the M3R protein complex or the positive control pmEpac2, 
following acceptor photobleaching of a region of the plasma membrane (dotted box). Scale bar, 10 µm. 
(I) FRET efficiency at the plasma membrane between M3R-CFP and YFP-tagged components of the 
protein complex, calculated from acceptor photobleaching FRET experiments from two regions of 
interest (ROI) per cell with four cells analyzed per biological replicate (n=24 ROIs). Data are expressed 
as the mean ± S.E.M. of n ROIs. * p<0.05 and *** p<0.001 versus M3R-CFP/Gαs-YFP FRET 
efficiency, Kruskal-Wallis with Dunn’s multiple comparison test; ^ p<0.05 and ^^^ p<0.001 versus 
M3R-CFP/Gαs-YFP FRET following conversion to binary values (1 = FRET, 0 = no FRET) then Chi-
square test. (J) Cartoon of the pre-assembled M3R signaling complex required for responses to 
femtomolar concentrations of CCh. Stimulation of cells with 1 fM CCh activates a Gαq/11-Gβγ-PKC–
mediated stimulation of AC2 that depends on AKAP79 and β-arrestins 1 and 2. This increase in cAMP 
causes the sequential activation of PKA and PDE4D3, which opposes the increase in cAMP. Hierarchy 
of proteins within the cartoon is based on reported protein-protein interactions (5, 55, 63).  
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Fig. 5. Stimulation of the β2AR and M3R by femtomolar concentrations of ligand activates 
sustained and compartmentalized kinase signaling. (A–F) Single native cells were stimulated with 
vehicle, or the indicated concentration of Iso for 20 min. (A) ERK activity detected in the nucleus of 
HEK293 cells using the FRET biosensor, EKAR, which is reversibly phosphorylated by ERK and 
targeted to the nucleus (nucEKAR). (n=118-133 cells). Data are normalized to the maximal ERK 
response (F/FMax). (B) Representative ratiometric pseudocolor images of cells from (A) at the indicated 
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time points following stimulation. Scale bar, 10 µm (C) ERK activity detected in the cytosol using the 
cytoEKAR FRET biosensor or nucleus (nucEKAR) of HEK293 cells. Some cells were stimulated with 
1 fM CCh instead of Iso for 20 min. (n=13-130 cells). Data is represented as the 20 min area under the 
curve (AUC). (D) ERK activity detected in the nucleus of human cardiac fibroblasts (CFs). (n=38-61 
cells). Data are normalized to the baseline ERK response (F/F0). (E) cAMP detected at the plasma 
membrane in HEK293 cells. (n=31-44 cells). Data are normalized to the maximal cAMP response 
induced after 20 min (F/FMax). (F) cAMP detected at the plasma membrane of human CFs. (n=22-53 
cells). Data are normalized to the baseline cAMP response (F/F0). (G-L) Single native cells were 
stimulated with vehicle or the indicated concentration of CCh for 20 min. (G) PKC activity detected in 
the cytosol of HEK293 cells using the FRET biosensor, CKAR, which is reversibly phosphorylated by 
PKC. (n=185-226 cells). Data are normalized to the maximal PKC response induced after 20 min 
(F/FMax). (H) Representative ratiometric pseudocolor images of cells from (G) at the indicated time 
points following stimulation. Scale bar, 10 µm (I) PKC activity detected at the plasma membrane 
(pmCKAR) or in the cytosol (cytoCKAR) of HEK293 cells. Some cells were stimulated with 1 fM Iso 
instead of CCh. (n=10-175 cells). Data is represented as the 20 min AUC. (J) PKC activity detected in 
the cytosol of human CFs. (n=69-124 cells). Data are normalized to the baseline PKC response (F/F0). 
(K) cAMP detected at the plasma membrane of HEK293 cells. (n=32-44 cells). Data are normalized to 
the maximal cAMP response induced after 20 min (F/FMax). (L) cAMP detected at the plasma 
membrane of human CFs. (n=31-50 cells). Data are normalized to the baseline cAMP response (F/F0). 
All cells were stimulated at 0 min, and a maximal ERK, PKC, or cAMP response (Max.) was induced 
after 20 min with PDBu (ERK), PDBu plus phosphatase inhibitors (PKC), or forskolin plus IBMX and 
PGE1 (cAMP). Individual cells were analyzed from experiments performed on three independent 
occasions. Data are expressed as the mean ± S.E.M. of n cells. *** p<0.001 versus vehicle control, 
two-way ANOVA with Sidak’s multiple comparison test. 
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Fig. 6. Activation of the β2AR and M3R by femtomolar concentrations of ligand causes distinct 
whole cell responses. (A) Representative hierarchical clustering of proteins with increased (blue) or 
decreased (red) abundance in native HEK293 cell populations following stimulation with vehicle, 1 fM 
or 100 nM Iso, or 1 fM or 10 µM CCh for 4 h. Data are expressed as Z-scores of the ligand-stimulated 
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change in protein abundance compared to vehicle (see also Table S3). (from n=3 independent 
experiments).  (B) Proteins with a significant increase or decrease in abundance in native HEK293 cells 
following stimulation with Iso or CCh were classified by Gene Ontology (GO) terms and grouped into 
the indicated categories. A GO biological process term was included if it occurred in at least two out of 
the three independent experiments. (C) Log2 change in protein abundance in the indicated native 
HEK293 treatment groups versus vehicle control for SF3B5, TXNL4A, RPS21, GUF1, and TXNDC9, 
all of which are involved in RNA processing and protein synthesis. (n=3). (D-E) GFP fluorescence in 
single native HEK293 cells expressing the pEF1α-GFP reporter following stimulation with vehicle, 1 
fM or 100 nM Iso (D; n=196-204 cells), or 1 fM or 10 µM CCh (E; 177-194 cells) for 4 h. Individual 
cells were analyzed from three independent experiments. Data are expressed relative to baseline 
fluorescence (F/F0). (F) GFP fluorescence in single human cardiac fibroblasts (CF) expressing the 
pEF1α-GFP reporter following stimulation with vehicle, 1 fM Iso, or 100 nM Iso for 4 h. (n=64-107 
cells). Individual cells were analyzed from four independent experiments. Data are expressed as 
relative fluorescence units (RFU) per cell. (G) GFP fluorescence in single human CFs expressing the 
pEF1α-GFP reporter following stimulation with vehicle, 1 fM CCh, or 10 µM CCh (n=109-121 cells), 
and activation of Cdc42, as measured by the Raichu-Cdc42 FRET biosensor which detects GDP/GTP 
binding, in single human CFs following stimulation with vehicle, 1 fM Iso, or 100 nM Iso (n=133-178 
cells) expressed as the 4 h area under the curve (AUC). (H) Log2 change in protein abundance in the 
indicated native HEK293 treatment groups versus vehicle control for GGA1, PDE6D, ILK, VPS52, 
and GPSM1, all of which are involved in protein trafficking and cytoskeletal networks. (n=3). (I–J) 
Activation of Cdc42 in single native HEK293 cells following stimulation with vehicle, 1 fM or 10 µM 
CCh (I; n=305-323 cells), or 1 fM or 100 nM Iso (J; n=304-401 cells) for 4 h. Individual cells were 
analyzed from three independent experiments. Data are expressed relative to baseline FRET (F/F0). (K) 
Activation of Cdc42 in single human CFs following stimulation with vehicle, 1 fM CCh, or 10 µM 
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CCh for 4 h. (n=150-159 cells). Individual cells were analyzed from three independent experiments. 
Data are expressed relative to baseline FRET (F/F0). All data are expressed as the mean ± S.E.M. of n 
cells or independent experiments. * p<0.05 and ** p<0.01 versus vehicle control, two-way ANOVA 
with Dunnett’s multiple comparison test (C, H). *** p<0.001 versus vehicle control, two-way ANOVA 
(D, F, I, K). 
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Fig. 7. GPCR signaling complexes respond to femtomolar concentrations of ligand. GPCRs exist 
in pre-assembled protein complexes at the plasma membrane. (1) Simulation of stochastic ligand-
receptor binding kinetics reveals that the addition of a 1 fM solution of ligand under our assay 
conditions would result in an average of one to two binding events per cell within 5 min. (2) One–two 
binding events stimulates strong signal amplification, which depends on a pre-assembled protein 
complex at the plasma membrane and results in (3) a relatively slow and gradual increase in the signal 
over time. (4) Addition of a high concentration solution of ligand (100 nM Iso or 1 µM CCh) results in 
a much greater number of binding events and activates receptors that are present in pre-assembled 
complexes as well as any uncomplexed receptors. (5) The resulting activation stimulates a signal that is 
qualitatively different from that elicited by ultra-low ligand concentrations, such as (6) no signal (CCh-
stimulated cAMP, EF1α gene transcription, or Cdc42 activity) or (7) a more rapid increase in the signal 
that then declines (Iso-stimulated cAMP, nuclear ERK, or cytosolic PKC). 
